Regulation of Schwann cells and osteoclasts with an emphasis on NF1-deficient cells by Pennanen, Paula
TURUN YLIOPISTON JULKAISUJA –  ANNALES UNIVERSITATIS TURKUENSIS
SARJA - SER. D OSA  - TOM. 1434  | MEDICA - ODONTOLOGICA | TURKU 2019
REGULATION OF SCHWANN
CELLS AND OSTEOCLASTS
WITH AN EMPHASIS ON
NF1-DEFICIENT CELLS
Paula Pennanen
31123633_Vaitoskirja_Paula_Pennanen_Laaketiet_tdk_kansi_wire_B5_1705.indd   1 17.5.2019   8.25

TURUN YLIOPISTON JULKAISUJA –  ANNALES UNIVERSITATIS TURKUENSIS
SARJA - SER. D OSA  - TOM. 1434 | MEDICA - ODONTOLOGICA | TURKU 2019
Paula Pennanen
REGULATION OF SCHWANN 
CELLS AND OSTEOCLASTS 
WITH AN EMPHASIS ON 
NF1-DEFICIENT CELLS
31123633_Vaitoskirja_Paula_Pennanen_Laaketiet_tdk_sisus_B5_1705.indd   1 17.5.2019   8.20
Supervised by
Professor Juha Peltonen, MD, PhD
Institute of Biomedicine
University of Turku, Turku, Finland
Docent Sirkku Peltonen, MD, PhD.
Department of Dermatology
University of Turku, Turku, Finland
University of Turku 
Faculty of Medicine
Institute of Biomedicine
Cell Biology and Anatomy and
Dermatology and Venereal Diseases
Turku Doctoral Programme of Molecular Medicine
(TuDMM)
Reviewed by
Professor Juha Tuukkanen, DDS, PhD
Department of Anatomy and Cell Biology
Institute of Cancer Research and
Translational Medicine
University of Oulu, Oulu, Finland
Professor Mikko Lammi, PhD
Department of Integrative Medical
Biology
Umeå University, Umeå, Sweden
Opponent
Professor Petteri Nieminen, DTh, 
DMedSci, PhD
Faculty of Health Sciences, School of
Medicine
Institute of Biomedicine/Anatomy
University of Eastern Finland, Kuopio,
Finland
The originality of this thesis has been checked in accordance with the University of 
Turku quality assurance system using the Turnitin OriginalityCheck service.
Cover Image: Background photograph of human osteoclast cell in culture by Paula 
Pennanen.
ISBN 978-951-29-7696-6 (PRINT)
ISBN 978-951-29-7697-3 (PDF)
ISSN 0355-9483 (Print)
ISSN 2343-3213 (Online) 
Grano Oy - Turku, Finland 2019
31123633_Vaitoskirja_Paula_Pennanen_Laaketiet_tdk_sisus_B5_1705.indd   2 17.5.2019   8.20
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
     To my Family 
 
31123633_Vaitoskirja_Paula_Pennanen_Laaketiet_tdk_sisus_B5_1705.indd   3 17.5.2019   8.20
Abstract 
ABSTRACT 
Paula Pennanen: REGULATION OF SCHWANN CELLS AND OSTEOCLASTS 
WITH AN EMPHASIS ON NF1-DEFICIENT CELLS University of Turku, Faculty 
of Medicine, Institute of Biomedicine, Cell Biology and Anatomy & Dermatology and 
Venereal Diseases, Turku Doctoral Programme of Molecular Medicine (TuDMM), 
Annales Universitatis Turkuensis, Medical-Odontologica, Turku, Finland, 2019 
 
Neurofibromatosis type 1 (NF1) is a dominantly inherited cancer predisposition 
syndrome, which affects one in 2000 individuals worldwide. NF1 exhibits a variety of 
clinical symptoms. Neurofibromas, the hallmarks of NF1, carry two different genotypes 
of Schwann cells: cells with a germline mutation and a healthy NF1 allele (NF1+/-) and 
those with an inactivation of both alleles (NF1-/-). These tumors typically start to appear 
during puberty, and their number and size grow during pregnancy indicating hormone 
responsiveness. The present study showed that cultured NF1-/- Schwann cells were more 
sensitive to the effects of estradiol, testosterone, and human chorionic gonadotropin 
(hCG) than NF1+/- cells.  
Multinucleated osteoclasts are responsible for bone resorption and actin ring formation 
is essential to bone resorption. The dynamic actin structure undergoes rapid changes and 
plays several roles including cellular movement and maintenance of the cell shape. The 
osteoclast actin structure consists of a podosome belt with a loose actin “cloud” on its 
top. STED and confocal microscopy revealed a new insight into osteoclast actin 
structure. This was a curved and branched actin structure extended from the substratum 
level to the top of the cell co-localizing with membrane lipids. In addition, thick actin 
containing micrometer-level tubes were bridging adjacent osteoclasts above the level of 
the substratum.  
The roles of the Ras/PI3K/Akt/mTOR, Ras/Raf/MEK1/2/ERK1/2, calcium-PKC, and 
p38 signaling pathways in human osteoclast differentiation and bone resorption were 
evaluated. Down-regulation of most of these pathways by chemical inhibitors decreased 
the number of osteoclasts from NF1 patients and controls. However, inhibition of p38 
increased osteoclastogenesis but not the function of the cells. In addition, inhibition of 
Ras increased the number of control osteoclasts but decreased the number of NF1 cells. 
We found that the number of osteoclasts appeared to correlate with the phosphorylation 
of ERK1/2, which may act as a key driver of human osteoclast differentiation.  
The aim of this in vitro study was to further develop, characterize, and test culture 
conditions for cell types involved in the pathogenesis of two distinct hallmark lesions of 
NF1. Specifically, these lesions include the neurofibroma tumors largely composed of 
Schwann cells; and the skeletal lesions such as osteoporosis and false joints, where 
osteoclasts apparently play a major role.  
Keywords: Neurofibromatosis 1, Schwann cell, osteoclast, actin, signaling pathway
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Tiivistelmä 
TIIVISTELMÄ 
Paula Pennanen: Schwannin solut neurofibroomien ja osteoklastit luun hajotuksen 
säätelijöinä. Esimerkkinä solut, joilla on NF1 geenin mutaatio. Turun yliopisto, 
Lääketieteellinen tiedekunta, Biolääketieteen laitos, Solubiologia ja anatomia & Iho- ja 
sukupuolitautioppi, Turun molekyylilääketieteen tohtoriohjelma (TuDMM), Annales 
Universitatis Turkuensis, Medica-Odontologica, 2019.  
Neurofibromatoosi tyyppi 1 (NF1) on vallitsevasti periytyvä syöpätyypeille altistava 
oireyhtymä, jonka esiintyvyys on maailmanlaajuisesti 1/2000. NF1 sairauteen liittyy 
useita erilaisia kliinisiä löydöksiä. Neurofibroomat ovat NF1 sairauden keskeisimpiä 
tunnusmerkkejä, jotka sisältävät kahden eri genotyypin Schwannin soluja: osassa 
soluista on heterotsygoottinen NF1+/- genotyyppi, jossa toinen alleeli on toimiva, kun 
taas osalle soluista on tapahtunut toisenkin alleelin katoaminen NF1-/-. Neurofibroomilla 
on taipumus ilmestyä murrosiän aikana ja niiden koko sekä määrä kasvavat raskauden 
aikana. Kasvainten ajatellaan reagoivan hormoneihin. Tässä tutkimuksessa osoitettiin, 
että erityisesti NF1-/- genotyypin Schwannin solut ovat erityisen herkkiä estradiolille, 
testosteronille ja koriongonadotropiinille.  
Monitumaisten osteoklastien tehtävä on hajottaa luuta. Aktiinirenkaan muodostuminen 
on välttämätöntä luun hajotukselle. Aktiinin dynaaminen rakenne muuttuu nopeasti ja 
aktiinilla on useita rooleja solujen liikkumisesta solun tukirangan muodostumiseen. 
Osteoklastien aktiinirakenne muodostuu niin kutsutusta podosomivyöstä ja sen päällä 
olevasta löyhästä aktiini pilvestä. Väitöskirjassa tutkittiin STED- ja 
konfokaalimikroskopian avulla osteoklastien aktiinirakennetta. Tutkimuksessa 
havaittiin, että taipuisa ja haarautuva aktiinirakenne ulottui osteoklastin kasvualustalta 
solun yläosaan asti. Tutkimuksessa löydettiin mikrometrin kokoisia tunneleita kahden 
eri osteoklastin välillä, jotka kulkeutuivat yhdestä solusta toiseen.  
Väitöskirjassa tutkittiin Ras/PI3K/Akt/mTOR, Ras/Raf/MEK1/2/ERK1/2, kalsium-
PKC, and p38 signalointiteiden roolia osteoklastien erilaistumisessa. Useimpien 
signalointiteiden todettiin vähentävän osteoklastien erilaistumista sekä kontrolli että 
NF1-potilaiden soluilla. Tutkimuksessa havaittiin, että p38 signaloinnin estäminen lisäsi 
osteoklastien erilaistumista molemmilla tutkituilla solutyypeillä. Lisäksi havaittiin, että 
Ras-signaloinnin estäminen lisäsi kontrolli solujen määrää, kun taas NF1 potilaiden 
osteoklastien määrä väheni. Väitöskirjatutkimuksessa todettiin osteoklastien määrän 
korreloivan ERK1/2 fosforylaation kanssa, joka saattaa olla osteoklastien erilaistumisen 
avaintekijä. Tämän in vitro tutkimuksen tarkoituksena oli tutkia soluja, jotka ovat 
osallisina NF1-sairauden patogeneesissä ja erityisesti sairauden keskeisimmissä 
tunnusmerkeissä. Näihin kuuluvat ihon neurofibroomat, jotka koostuvat suurelta osin 
Schwannin soluista sekä luuston leesiot, kuten osteoporoosi tai valenivelen 
muodostuminen, joissa osteoklasteilla on ilmeisesti merkittävä rooli. 
Avainsanat: Neurofibromatoosi 1, Schwannin solu, osteoklasti, aktiini, signalointitie
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1 INTRODUCTION 
Neurofibromatosis 1 (NF1) is a fully penetrant neurocutaneous and skeletal syndrome 
caused by mutations in the NF1 gene. If one parent carries the NF1 mutation, then half 
of the children inherit the disease from their parent. The other half inherits the disease 
from the healthy parents through spontaneous mutation, which has occurred during 
formation of gametes. A NF1 patient germline mutation of the NF1 gene (NF1+/-) is in 
each cell. NF1 is as common in women as in men. However, gender influences 
symptoms of the disease. NF1 affects multiple organs, and symptoms vary between 
individuals even in the same family. There is no cure for NF1. Treatment of the disease 
focuses on treatment of the symptoms. 
Neurofibromas are the hallmarks of NF1, and neurofibromas are present in half of the 
10-year–old patients. During the age of 20, 80% of the patients have neurofibromas. 
Neurofibromas are benign skin tumors, which cause severe esthetic or social burden. 
These tumors arise during early puberty, and increase in amount and size during 
pregnancy. There is no medical treatment against these tumors.  
The NF1 gene plays a role in bone remodeling, and half of the patients have some kind 
of bone abnormalities. Bone loss affects everybody and is part of age-related bone loss. 
Bone remodeling is based on bone resorption by osteoclasts and bone formation by 
osteoblasts, and this process occurs throughout life. The osteoclast cytoskeleton is a 
dynamic structure that enables cell movement, invasion, cell shape, and positioning of 
the cell organelles. Actin is one of the main types of filaments of the osteoclasts, and it 
is different in osteoclasts according to their substratum, on glass, or on bone. On glass, 
actin forms a podosome belt on the substratum level with an actin cloud on its top. On 
bone, actin forms a sealing zone. Actin plays a role in intracellular membrane transport. 
Multiple signaling pathways are involved in differentiation of osteoclasts. Excess 
differentiation of osteoclasts is involved in different bone diseases, such as osteoporosis. 
Therefore, a deeper understanding of osteoclast molecular mechanisms and cellular 
behaviors is important.  
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2 REVIEW OF LITERATURE 
2.1 Neurofibromatosis 1 (NF1) 
2.1.1 The clinical diagnosis of NF1 
Neurofibromatosis 1 is an autosomal dominant disorder affecting 1:2000 people 
(Uusitalo et al., 2014). The clinical diagnosis of NF1 requires the meeting of two or 
more criteria of the disease, which has been established in 1987 by the National Institute 
of Health (NIH) (Stumpf et al., 1988). Diagnosis is based on the presence of two of the 
following: six or more café-au-lait spots (pigmented spots on the skin, >5 mm in pre-
pubertal patients, >15 mm in post-pubertal patients); two or more neurofibromas of any 
type or one or more plexiform neurofibroma; axillary or inguinal freckling; an optic 
glioma; two or more Lisch nodules in the eyes (small dark spots on iris); a typical 
skeletal abnormality for NF1, such as pseudarthrosis or dysplasia of long bone; and a 
first degree relative with NF1 by the above criteria. Other findings related to NF1 are 
scoliosis, short stature, learning disabilities, and macrocephaly (Boyd et al., 2009). 
The NF1 phenotype is 100% penetrant, and by the age of 8, nearly all NF1 patients have 
2 or more of the symptoms included in the NIH Diagnostic criteria (DeBella et al., 
2000; Duong et al., 2011). NF1 affects multiple organs, and the symptoms are highly 
variable and unpredictable even within the same family (Viskochil, 2002). 
2.1.2 Genetic background of NF1 
Neurofibromatosis 1 is a result of a germline mutation in the NF1 tumor-suppressor 
gene, which is located on chromosome 17, band q11.2. The size of this large gene is 
350 kilobases, which may partly explain the high number of mutations. Half of the NF1 
patients have inherited their disease from their parents, and the other half has no family 
history due to a spontaneous de novo mutation (Hirbe and Gutmann, 2014; Parada, 
2000). 
The NF1 gene encodes a tumor suppression protein called neurofibromin, which is one 
of the GTPase-activating proteins. It consist of 2818 amino acids, and its molecular 
weight is 280 kDa (DeClue et al., 1991). Neurofibromin acts as a Ras-GTPase-
activating protein (Ras-GAP), which functions as a negative regulator of Ras by 
converting active Ras-GTP to inactive Ras-GDP (Johnson et al., 1994; Le and Parada, 
2007). Mutation in the NF1 gene causes loss of functional neurofibromin. This, in turn, 
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leads to hyperactive cells growing and dividing in an uncontrolled way that can lead 
tumor formation (Ferner and Gutmann, 2013; Heervä et al., 2010; Parada, 2000). This is 
presented in Figure 1.  
Figure 1. Neurofibromin as a negative regulator of Ras signaling. 
The molecular diagnostics of this disease is still difficult, partly due to the large size of 
the NF1 gene, because over 2800 different germline mutations have been reported 
(Koczkowska et al., 2018). All patients with NF1 seem to carry a heterozygous 
mutation of the disease, and a loss of both alleles of the NF1 gene in the germline has 
not been shown (Jouhilahti et al., 2011b). The spectrum of the mutations in NF1 is very 
wide, but only a few phenotype-genotype correlations have been identified (Pasmant et 
al., 2012). Microdeletion of 17q11.2, meaning deletion of the entire NF1 gene and 
surrounding genes, is known to cause a severe form of NF1 in 5 – 10% of patients 
(Kluwe et al., 2004; Pasmant et al., 2010). Mild NF1 disease occurs in a mosaic form, 
when an individual has two genetically unequal cell lines as a result of mutation 
occurring early during embryonic development (Boyd et al., 2009; Colman et al., 1996). 
According to Ars et al. (2000), the most common mutations of NF1 are those affecting 
mRNA splicing (Ars et al., 2000). Other mutations in the NF1 gene include point 
mutations, insertions, and deletions (Koczkowska et al., 2018).  
There are also other genetic diseases belonging to group of RASopathies, syndromes 
caused by germline mutations in Ras/mitogen-activated protein kinases (MAPK)-
pathway genes. These syndromes include, inter alia, Noonan, Costello, cardio-facio-
cutaneous, and Legius syndromes (Tidyman and Rauen, 2010). RASopathies, especially 
Legius syndrome that is caused by mutations in the SPRED1 gene, may be mistaken for 
NF1 disease, because these syndromes share the same clinical features, such as axillary 
freckling, café-au-lait spots, and learning disabilities (Brems and Legius, 2013). Based 
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on the similarity of the clinical features of these diseases, it is important to understand 
the overlapping pathophysiology of NF1 and these other RASopathies. 
Neurofibromatosis type 2 (NF2) is caused by mutations in the NF2 gene located on 
chromosome 22, band q12.2. NF2 syndrome is much less common than NF1. The 
hallmark of NF2 are bilateral vestibular schwannomas (Evans, 2015).  
2.1.3 Tumors in NF1 
The benign cutaneous tumors called neurofibromas cause the main disease burden in 
adults and are the hallmarks of neurofibromatosis 1. Neurofibromas are present in half 
of 10-year-old patients and stand in 80 % of 20-year-old NF1 patients (DeBella et al., 
2000; Duong et al., 2011; Kodra et al., 2009). The number of these tumors is highly 
variable among patients, and the number can be few, hundreds, or even thousands 
(Verma et al., 2018). Cutaneous neurofibromas are located in the dermis, and they 
rarely cause medical problems other than tenderness or itch but may cause severe 
esthetic or social burden. There is no cure or way to stop the growth of these tumors, 
although removal of neurofibromas with a carbon dioxide laser offers a feasible method 
to decrease the number of tumors (Chiang et al., 2012). 
Internal neurofibromas are major disadvantages in NF1. Neurofibromas can be present 
underneath the dermis in the subcutis or in larger nerves within muscles. Compared to 
cutaneous neurofibromas, subcutaneous tumors cause more often pain and neurological 
symptoms (Ferner, 2010; Khosrotehrani et al., 2005). 
Plexiform neurofibromas arise from multiple nerve fascicles, tend to grow along the 
nerve length, and extend into surrounding structures. They are often found in young 
children, can be present at a time of birth, and can continue growing during adolescence 
(Joshi et al., 2015; Nguyen et al., 2011). Over half of the NF1 patients have internal 
plexiform neurofibromas, which can be detected with whole body magnetic resonance 
imaging (MRI). Although these tumors are benign, they can cause severe symptoms 
such as functional disability, disfigurement, and a danger to life by becoming malignant 
(Jett et al., 2015; Korf, 1999; Mautner et al., 2008). Plexiform tumors are not 
radiosensitive, and their response to chemotherapy is low, so the most effective 
treatment is surgery (Wise et al., 2005).  
Subcutaneous and plexiform neurofibromas can develop into malignant peripheral nerve 
sheath tumors (MPNSTs), but MPNSTs can also arise sporadically (Ferner and 
Gutmann, 2002). MPNSTs in NF1 affect mostly young and middle-aged adults. They 
tend to metastasize early, and MPNSTs are the leading cause of mortality in NF1. The 
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lifetime risk for MPNST is about 16%, and 5-year survival is only 30-50% (Evans et al., 
2002; Uusitalo et al., 2016). 
2.1.4 Skeletal lesions and osteoporosis in NF1 
Half of the NF1 patients have some kind of bone abnormalities. Skeletal manifestations 
in NF1 can be divided into focal and generalized lesions. The focal lesions include, 
among others, scoliosis, pseudarthrosis of a long bone, macrocephaly, and sphenoid 
wing dysplasia. Generalized skeletal lesions include short stature and low bone mineral 
density (BMD) including osteopenia and osteoporosis (Elefteriou et al., 2009; Ferner, 
2010). 
Scoliosis affects over 20% of NF1 patients. This spinal deformity’s severity may vary 
from mild (i.e., idiopathic scoliosis) to severe and can be life-threatening curvatures 
(i.e., dystrophic scoliosis) (Akbarnia et al., 1992; Tsirikos et al., 2005). The 
pathophysiology of pseudarthrosis is not known. However, double inactivation of the 
NF1 gene in mesenchymal progenitors from the periosteum has been considered 
important, and it has been suggested that this lesion is due to altered neurofibromin-Ras 
signaling. Also markedly high numbers of osteoclasts have been found in histological 
analysis of NF1-related pseudarthrosis tissues. Pseudarthrosis of long bones affects 5% 
of NF1 patients, and 50 - 80% of patients with pseudarthrosis have NF1 (Heervä et al., 
2010; Sant et al., 2015; Stevenson et al., 1999). Sphenoid wing dysplasia affects 
approximately 5% of NF1 patients. These patients suffer from partial or complete 
absence of the greater wing of the sphenoid, and the best treatment modality is a 
surgical procedure (Lotfy et al., 2010). 
Macrocephaly (i.e., unusually large head size) is one of the clinical signs of NF1, and it 
occurs in at least half of the NF1 patients, especially in children (Karvonen et al., 2013; 
Morris et al., 2016). NF1 children are shorter compared to age-mates, which partly 
explains the fact that NF1 adults are shorter than unaffected counterparts. Short stature 
affects half of the NF1 patients (Soucy et al., 2013; Vassilopoulou-Sellin et al., 1995).  
Many studies have shown that low bone mineral density (BMD) is common in NF1 
(Heervä et al., 2012; Kuorilehto et al., 2005; Lammert et al., 2005a). The lowest BMD 
values have been obtained from load-bearing sections of the body, such as legs and 
spine (Kuorilehto et al., 2005). In addition to an age-related decrease of BMD, 
osteoporosis and osteopenia are common in NF1 patients, and osteopenia progresses 
often to osteoporosis (Brunetti-Pierri et al., 2008; Heervä et al., 2013). 
Osteoporosis is a major public health problem in the world. Low BMD, low intake of 
vitamin D and calcium, hormonal factors, gender, family history for fractures, lifestyle 
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choices (i.e., tobacco, alcohol, spending a lot of time sitting), and certain diseases like 
celiac disease increase the risk of osteoporosis. Aging people and postmenopausal 
women are especially at a high risk for fractures in the hip, the spine, and other bones 
(Finkelstein et al., 2008; Lane, 2006). During the normal lifespan, the amount of bone 
tissue keeps growing and reaches its maximum strength and density at around the age of 
30. Thereafter, bone mass begins to drop with age. The decrease in estrogen production 
after menopause is associated with reduced bone mass, which further increases the risk 
of osteoporosis in women (O'Flaherty, 2000). Osteoporosis is usually diagnosed 
clinically with dual-energy X-ray absorptiometry (DXA), when a person’s BMD T-
score is equal to or more than 2.5 standard deviations below the mean BMD of the 
population. Other methods that can be used to diagnose osteoporosis are quantitative 
computer tomography and quantitative ultrasound (Kanis, 2002). 
2.1.5 Other manifestations of NF1 
Optic pathway gliomas are the most common central nervous system benign tumors in 
NF1. Usually these tumors arise in young children, and they are present approximately 
in 20% of patients with NF1 (Rodriguez et al., 2008). Although most optic gliomas are 
low-grade tumors, they can cause vision disturbances, proptosis (e.g., bulging of the 
eye), pain, and disturbances in hormone production. Hormonal problems emerge, when 
the tumor spreads to the hypothalamus causing early puberty (Boyd et al., 2009; 
Listernick et al., 2007). There is no effective treatment available for symptomatic optic 
pathway glioma. Radiotherapy is not recommended, because it may lead to secondary 
malignancies later. Observation, especially for non-symptomatic tumors in children, is 
recommended. Also chemotherapy is accepted, if the severity of the symptoms can be 
decreased (Thomas et al., 2015). Another ophthalmic features of NF1 are small, dome-
shaped, and light brown Lisch nodules, which are harmless and present in 95% of adults 
NF1 patients (Huson et al., 1987). 
Café-au-lait spots are hyperpigmented macules and are observed in 95% of patients with 
NF1. They are usually the first signs of NF1, and present at birth, or develop within first 
years of life (DeBella et al., 2000). Another cutaneous manifestation is freckles of 
skinfolds. This appears at the age of 3 to 5, and practically all adults have them. They 
are present in the area of the armpit, groins, neck, or under breasts (Boyd et al., 2009). 
Nevus anemicus, a localized area of pale spots, is also a common skin finding and may 
be useful in supporting the diagnosis of NF1 especially in children (Vaassen and 
Rosenbaum, 2016). 
A wide range of neurological problems is part of NF1 disease. Mild cognitive 
impairment, learning disabilities, and behavioral problems are seen in 50 to 80% of NF1 
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people. The intelligence of NF1 children is usually normal, although under the average 
value when compared to healthy children (Friedman, 2002; Lehtonen et al., 2013). 
Overall, the vast majority of NF1 manifestations are not life threatening, but they affect 
the quality of life (QoL) in different ways, such as causing aesthetic problems. 
Unpredictability of NF1 may also cause stress. Questionnaires to measure the QoL in 
NF1 are helpful in individual patient’s assessment (Ferner et al., 2017; Wolkenstein et 
al., 2001).  
2.2 Hormones 
Hormones may play a role in dermal neurofibromas of NF1 disease. These skin benign 
tumors start to grow during puberty, and their number and size increase during 
pregnancy (Posma et al., 2003; Roth et al., 2008a). Sex hormones mediate their effects 
by binding to their receptors. Cholesterol is the starting material for the biosynthesis of 
steroids (Figure 2). Cholesterol can be synthesized de novo from acetate by all tissues, 
especially the liver, or obtained from the diet. Low density lipoproteins (LDL) transfer 
cholesterol to the cells and high density lipoproteins (HDL) from the cells (Charlton-
Menys and Durrington, 2008). Cholesterol is converted to pregnenolone in the inner 
mitochondrial membrane by the CYP11A1 enzyme (Nebert and Russell, 2002). The 
steroidogenic acute regulator (STAR) plays an important role in lipid metabolism by 
transferring cholesterol from the outer mitochondrial membranes to inner mitochondrial 
membranes (Lin et al., 1995). Pregnenolone can be converted into progesterone by type 
1 3- hydroxysteroid dehydrogenase (HSD3B1) enzyme, which is located either in the 
ovarian theca cells or testis Leydig cells, or into 17α-hydroxypregnenolone and further 
to dehydroepiandrosterone (DHEA) by CYP17A1 (Miyabayashi et al., 2015; Ye et al., 
2011). Progesterone can be synthesized into 17-hydroxyprogesterone by CYP17A1 and 
further to  androstenedione (Miller and Auchus, 2011). 
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Figure 2. Sex hormone synthesis.  
2.2.1 Gonadotropins 
The biosynthesis of sex hormones is controlled through the feedback system of 
hypothalamus-pituitary-target tissue axis (Figure 3). Follicle stimulating hormone 
(FSH) and luteinizing hormone (LH) control ovarian steroid hormone biosynthesis and 
the development of the ovarian follicles in females. In males, LH and FSH stimulate the 
aromatization of estrogens and control the synthesis of testosterone.When more sex 
hormones are needed, the hypothalamus increases secretion of gonadotropin-releasing 
hormone (GnRH), which further stimulates the secretion of LH or FSH into general 
circulation. (Bain, 2007; Plant, 2015; Velarde, 2014).  
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Figure 3. The feedback system of hypothalamus-pituitary-target tissue axis. 
Human chorionic gonadotropin (hCG) and LH share the same receptor (LH/CGR) and 
their molecular structures are similar. However, they play different roles in reproductive 
physiology (Choi and Smitz, 2014). The receptor is found in the gonads, ovary, testis, 
skin, breast, adrenals, and neuroendocrine cells (Theofanakis et al., 2017). LH is 
responsible for regulating gonadal steroidogenesis and ovulation through the 
hypothalamic-pituitary-gonadal axis (Liu et al., 2007; Takahashi et al., 2016). hCG is a 
glycoprotein, which is present in four different isoforms and has a crucial role in 
gaining and maintaining pregnancy. It is produced by syncytiotrophoblast cells, and its 
mission is to stimulate the secretion of progesterone in the corpus luteum, stimulate 
angiogenesis within a pregnant uterus, and differentiate cytotrophoblasts into 
syncytiotrophoblasts (Cole, 2010). Pituitary hCG is present in men and women, thus, it 
is produced by gonadotrophic cells of the anterior pituitary. Pituitary hCG mimics LH 
function and may initiate the ovulation (Choi and Smitz, 2014).  
LH cannot support pregnancy, however, hCG is also used clinically to induce ovulation 
in assisted fertilization (Stenman et al., 2006). Free -hCG is found at low levels during 
normal pregnancy, but it is also known to promote cancer cell growth (Stenman et al., 
2006). hCG is also expressed in malignant tumors, and it seems to play a role in the 
formation of tumors microvascular channels reminding of small blood vessels, which 
provide nutrients to tumor (Gao et al., 2016). In cancer predisposition syndrome NF1, 
an increase in the size and number of skin neurofibromas during pregnancy has been 
reported (Xiong et al., 2015). The connection between growing neurofibromas and 
pregnancy is unknown. However, it maybe that hormones influence on the growth of 
cells, especially Schwann cells, inside of the neurofibromas (Roth et al., 2008b). The 
influence of hCG seems to promote the cell signaling of cAMP, but also the 
extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation (Riccetti et al., 
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2017) and it is known that the phosphorylation of ERK1/2 promotes the 
dedifferentiation of Schwann cells (Napoli et al., 2012). 
2.2.2 17--Estradiol 
Estrogens are responsible for pubertal development, regulation of the menstrual cycle, 
increasing bone mass and muscle strength, and improving cardiovascular systems (Hall 
et al., 2001; Messinis et al., 2014; Shirtcliff et al., 2009; van den Beld et al., 2000). The 
activation of estrogen is mediated through the estrogen receptors ERα and ER, which 
translocate to the nucleus (Marin-Castaño et al., 2003). The classical ligand-dependent 
pathway requires estradiol attachment to the ER following a conformational change of 
the complex, which leads to translocation of the estradiol/ER complex to the nucleus 
(Hall et al., 2001). There are several signaling pathways activating under the including 
of  estradiol, which are Ras/Raf/mitogen-activated protein kinase (MEK)/ERK and 
phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of 
rapamycin (mTOR) (Driggers and Segars, 2002). Estrogen is mainly produced in the 
ovaries in addition to testis, adipose tissue, brain, vascular endothelium, bone cells, and 
aortic smooth muscle cells (Simpson, 2003). Estrogen is the major female hormone and 
plays an important role also in males. There are four naturally occurring estrogens: 
estrone (E1), estradiol (E2), estriol (E3), and estetrol (E4). The most active form of 
estrogen is estradiol (17β-estradiol, E2) (Kuiper et al., 1997; Thomas and Potter, 2013). 
Estrogen is synthesized from androgens in many tissues through aromatase, which is 
found in many tissues and cells. Estradiol synthesis takes place, when aromatase 
converts androstenedione to estrone, and type 3 17- hydroxysteroid dehydrogenase 
(HSD17B1) finalizes the synthesis (Figure 2) (Hilborn et al., 2017; Stocco, 2012)  
The main burden of NF1 disease is neurofibromas affecting the quality of life (QoL) 
(Wolkenstein et al., 2001). The main cell type of neurofibromas are Schwann cells 
(Viskochil, 2003). It has been shown that neurofibromas, neurofibroma-derived 
Schwann cells and Schwann cells isolated from sciatic nerve contain ERs (Fishbein et 
al., 2007; Geller et al., 2008; Gu et al., 2018; McLaughlin and Jacks, 2003). 
Interestingly, E2 increases the proliferation and differentiation of Schwann cells (Chen 
et al., 2016). In addition, the influence of E2 were reported to increase the size of mouse 
xenograft model of malignant peripheral nerve sheat tumors (MPNSTs), which develop 
from Schwann cells (Li et al., 2010; Perrin et al., 2007). However, there are only few 
studies related to estrogen action on Schwann cells, although clinical findings show that 
neurofibromas appear during puberty. 
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2.2.3 Testosterone 
Testosterone plays many biological roles. It is needed for pubertal development, 
development of male reproductive tissues, increasing muscle and bone mass, has roles 
in hematopoietic and neural systems, and is necessary in the immune system (Davey 
and Grossmann, 2016). The effects of testosterone and other androgens are mediated 
through the androgen receptor (AR), which is expressed in many cells and tissues (Gao 
et al., 2005). When testosterone binds to AR, it induces a conformational change, 
dissociates proteins from the AR, which leads to translocation of the testosterone/AR 
complex to the nucleus, where it binds to androgen response elements (AREs) of DNA. 
This procedure leads to gene expression and recruitment of cofactor proteins and other 
signaling pathways (Gao et al., 2005; Tan et al., 2015). The testosterone/AR complex 
can also activate 2nd messenger pathways without binding to DNA, such as 
Ras/raf/MEK/ERK or PI3K/Akt (Liao et al., 2013). AR can even activate without 
androgen attachment as in hormone-resistant prostate cancer (Dehm and Tindall, 2006; 
Saraon et al., 2014). Testosterone is the major androgen in men, where it is mainly 
produced in testes Leydig cells (Shima et al., 2013). In women, testosterone is produced 
in ovaries and adrenal glands. It is synthesized from androstenedione by HSD17B3 or 
through DHEA conversion by HSD17B3 into androstenediol and further by HSD3B1 to 
testosterone (Burger, 2002; Roy et al., 2014). Testosterone can be further converted to 
dihydrotestosterone (DHT) by 5α-reduction in the prostate. It is responsible for the most 
of testosterone’s biological action (Luu-The et al., 2008). Testosterone (not DHT) can 
be synthesized to estradiol via aromatase, p450aro, in certain tissues, such as ovary, 
testis, bone, prostate, placenta, brain, adipose tissue, and breast carcinoma tissue 
(Stocco, 2012).  
Testosterone levels increase during pregnancy (O'Leary et al., 1991). Neurofibroma 
growth is related to hormonal influence. Androgen receptors are expressed in 
neurofibroma tumors and neurofibroma-derived Schwann cell cultures (Fishbein et al., 
2007). Androgen synthesis is few steps from progesterone synthesis, and it has been 
shown that 75% of the neurofibromas express progesterone receptors and progesterone 
increases the proliferation of Schwann cells (McLaughlin and Jacks, 2003; Overdiek et 
al., 2008). However, the role of androgens in Schwann cells is still unknown.  
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2.3 Pathogenesis of neurofibromas 
2.3.1 Structure and supporting cells of peripheral nerve  
The human nervous system can be divided into two sections: the central nervous system 
and the peripheral nervous system. Shortly, the central nervous system consists of the 
brain and the spinal cord, and peripheral nervous system consists of ganglia, cranial, 
and spinal nerves. The tissue of the peripheral nerve consists of several types of cells, 
e.g., Schwann cells, satellite cells, fibroblasts, adipocytes, perineurial cells, 
macrophages, and nerve cells, also called as neurons. Neurons (Figure 4) provide a fast 
pathway for electrochemical nerve impulses (Fu and Gordon, 1997; Richard et al., 
2014). 
 
Figure 4. Overview of the structure of a neuron. Dendrites branch from the soma of a 
neuron and allow the neuron to receive information. The information conducts down the 
axon and passes the information to an effector cell, e.g., a muscle cell. Schwann cells 
cover the axon to form a protective myelin sheath. The gaps between the Schwann cells 
are called the nodes of Ranvier.  
The outer layer of peripheral nerve is covered by a connective tissue called epineurium, 
which surrounds blood vessels and several axon bundles, also called as nerve fascicles. 
These axon bundles are enclosed by the perineurium. All axons, except those of the 
smallest sensory nerve endings, are coated by Schwann cells. Schwann cells may form 
the myelin layer or surround several axons without forming myelin. Axon-Schwann cell 
units are buried in connective tissue called endoneurium. Together, the epineurium, 
perineurium, and endoneurium form a protective covering of a peripheral nerve. The 
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collagen structure provides the strength of peripheral nerve, and adipocytes protect the 
nerve from pressure (Campbell et al., 2013; Peltonen et al., 2013).  
 
Figure 5. Structure of a peripheral nerve. The outer layer of the peripheral nerve is 
enclosed by connective tissue called epineurium. Inside of the epineurium there are 
multiple nerve fascicles, which are covered with perineurium. Nerve fascicles consist of 
bundles of axons, which are enclosed in the endoneurium. Blood vessels supply 
nutrients to peripheral nerve cells and are located between and inside the fascicles. 
2.3.2 Cellular structure of cutaneous neurofibromas 
Benign cutaneous neurofibromas are the hallmarks of NF1 disease. The rubbery 
consistency of neurofibromas is due to collagenous extracellular matrix (ECM), where 
Schwann cells, fibroblasts, perineurial cells, endothelial cells, and mast cells are 
embedded (Peltonen et al., 1988). In neurofibromas of NF1 patients, all the cells carry a 
constitutional mutation in the NF1 gene (NF1+/-). In addition, a subpopulation of 
Schwann cells also carry a second hit in the gene (NF1-/-) (Serra et al., 1997). 
Histological and in vitro studies have shown that the majority of the cell population in 
neurofibromas consists of Schwann cells and fibroblasts (Peltonen et al., 1988; Pummi 
et al., 2006). The fibroblasts’ main function is to support the structure of connective 
tissue. Fibroblasts are specialized for the secretion of ECM components such as Type I, 
III, and VI collagens, glycosaminoglycans, and other important glycoproteins such as 
fibronectin. Fibroblasts have the ability to migrate and secrete collagenous material into 
the wound further promoting wound healing. They also have the ability to synthesize 
laminin. Fibroblasts differ according to their tissue location; they are different, e.g., in 
skin or on bone matrix. It has been suggested that components of ECM can influence 
differentiation of immature fibroblasts (Ivey, 2017; Jaakkola et al., 1989a; Nomura et 
al., 1994; Olsen et al., 1989). Fibroblasts can be detected by the expression of CD34, 
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and it seems that neurofibroma fibroblasts originate from endoneurial fibroblasts 
(Hirose et al., 2003).  
The mission of perineurial cells is to form the perineurium surrounding a nerve fascicle, 
which consists of bundles of Schwann cells covering the axons. Perineurial cells 
produce laminin and secrete fibronectin and type I, III, and VI collagen. Claudin-1 can 
be used as a marker for perineurial cells (Jaakkola et al., 1989b; Peltonen et al., 1987; 
Pummi et al., 2006).  
Neurofibromas are dependent on blood supply, because blood vessels provide nutrients 
to the tumor. The linings of the blood vessels are formed by endothelial cells. 
Endothelial cells have the capacity to proliferate and form new vessels when necessary. 
Friedrich et al. (2015) showed that vascular invasion in NF1 neurofibromas was highly 
variable and presented a higher mean compared to vascular invasion of healthy control 
skin biopsies. However, there was no statistical difference between these two groups. 
NF1 neurofibromas may bleed when removed, and this may be because of alterations in 
the structure of the vascular wall (Friedrich et al., 2015).  
Collagen production is necessary for tumor formation. Mast cells of neurofibromas 
induce proinflammatory growth factors such as basic fibroblast growth factor (bFGF) 
and transforming growth factor-beta (TGF-beta), which in turn accelerates collagen 
production by fibroblasts (Yang et al., 2006). In addition, masts cells secrete platelet-
derived growth factor (PDGF) promoting vascular invasion of tumors (Bhowmick et al., 
2004; Yamabe et al., 2000). Masts cells are located in endo-, peri-, and epineurial 
structures of the peripheral nerves (Bienenstock et al., 1991). Histological studies have 
shown that mast cells are located differentially in NF1-related cutaneous and plexiform 
types of neurofibromas. In cutaneous neurofibromas, mast cells were located densely 
and throughout the tumor, while in plexiform tumors, the number of mast cells was 
lower, and they were located in the periphery of the tumor (Tucker et al., 2011).  
2.3.3 Origin of cutaneous neurofibromas 
Neurofibromas contain the same cell types as peripheral nerves allowing for speculation 
that neurofibromas arise from the small nerves or nerve branches (Jo and Fletcher, 
2014; Jouhilahti et al., 2011a). In normal peripheral nerve, axon Schwann cell units are 
shielded and sheltered by perineurial cells of perineurium (Piña-Oviedo and Ortiz-
Hidalgo, 2008). The most abundant cells in neurofibromas are Schwann cells, which are 
dissociated from nerves (Peltonen et al., 1988). The hyper-proliferation of the Schwann 
cells has been shown to be the initiator of these benign tumors. Part of the neurofibroma 
Schwann cells carry heterozygous NF1 mutation (NF1+/-), and the other part of 
Schwann cells carry also a second hit, leading to the inactivation of both alleles of the 
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NF1 gene (NF1-/-) (Serra et al., 1997). This is supported by the mouse studies showing 
that mice carrying only Nf1+/- mutation did not develop neurofibromas (Jacks et al., 
1994). However, mice (chimeric mice) injected with Nf1-/- embryonic stem cells into the 
blastocysts developed Nf1-/- cells and also high number of neurofibromas. This approach 
resembles the human condition, where part of the somatic cells carry a second hit of the 
NF1 gene (Cichowski et al., 1999). One view of neurofibroma development suggests 
that a second hit in part of the Schwann cells of the nerve initiates perineurium 
disruption and starts uncontrolled cell proliferation towards tumor growth (Colman et 
al., 1995; Serra et al., 1997; Zhu et al., 2002).  
Different studies with mice knockout models have shown that formation of 
neurofibromas require both Nf1+/- cells, such as mast cells and fibroblasts, and Nf1-/- 
Schwann cells in the microenvironment for tumor. Another study related to the stem 
cell niche, approaches the initiation of skin benign neurofibromas with alternative 
explanation (Jouhilahti et al., 2011a). Neurofibromas tend to locate nearby hair follicles, 
which are the source of multipotent stem cells. These multipotent neurofibroma-derived 
precursor cells had the potential to differentiate to Schwann cells, neurons, epithelial 
cells, and adipocytes which suggests that multipotent stem cells can be involved in the 
development of neurofibromas. 
2.3.4 Schwann cells in vivo and in vitro 
Schwann cells play a role in maintaining the peripheral nerve. Schwann cells originate 
from neural crest cells from where they differentiate first into Schwann cell precursors 
and further into immature Schwann cells, and finally to either myelinating or non-
myelinating Schwann cells (Jessen and Mirsky, 1997). Many growth factors regulate 
differentiation and proliferation of Schwann cells. Schwann cells express insulin 
receptors, and it is known that insulin activates MAPK and PI3K/Akt pathways, and 
further Schwann cell differentiation, survival, and myelination (Le Roith and Zick, 
2001; Russell et al., 2000; Shetter et al., 2011; Syroid et al., 1999).  
Neuregulins, such as heregulin can activate epidermal growth factor receptor (EGFR), 
because it contains a homology domain to epidermal growth factor (EGF), which binds 
to EGF receptors of erbB2 and erbB3 in Schwann cells. Long-term exposure with 
heregulin to gain change in gene expression stimulates Schwann cell proliferation 
together with forskolin. Heregulin activates MAPK and forskolin raises the cyclic 
nucleotide cyclic adenosine monophosphate (cAMP) and its principal target, the cAMP-
dependent protein kinase A (PKA) (Jessen and Mirsky, 1997; Rahmatullah et al., 1998; 
Seamon and Daly, 1981). It is known that cAMP is an essential route for many 
Schwann cell growth factors. The effect of cAMP to Schwann cell differentiation and 
Schwann cell proliferation acts through the cAMP-PKA pathway (Monje, 2015). The 
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NF1 gene plays a role in maintaining a balance between Ras and the level of cAMP 
(Kim et al., 2001). Loss of Nf1 leads to abnormal regulation of the cAMP-PKA 
pathway. A study showed that cAMP levels were multiple in Schwann cells cultured 
from Nf1-null mice and levels of cyclin D1 were increased compared to wild-type mice 
Schwann cell cultures. Loss-of-function of Nf1 seemed to promote the formation of 
cAMP (Kim et al., 2001). During the G1 phase of the cell cycle, cyclin D1 promotes the 
cell cycle independently. However, the activation of Ras is critical to promote the 
synthesis of cyclin D1 to continue the proliferation of the cells (Hitomi and Stacey, 
1999). Perhaps because of the hyperactive Ras in NF1, the level of cyclin D1 is elevated 
and the proliferation of Schwann cells is increased. Heregulin together with forskolin 
maintain high levels of cyclin D1, and therefore, maximal proliferation of Schwann 
cells in a cell culture (Kim et al., 1997; Rahmatullah et al., 1998).  
To detect the mature Schwann cells from the other cell types, a biomarker of S100B has 
been widely used. Schwann cells are also identified by their bipolar shape (Peltonen et 
al., 1988; Scarpini et al., 1988). Different mouse models have been developed to study 
the phenotypes and pathogenesis of NF1. Mouse models with NF1 patient-specific 
mutations showed that the frame and severity of the disease is depends on the mutation, 
and symptoms can vary from disorganized non-myelinating axons and neurofibromas to 
generation of non-viable mice (Li et al., 2016).  
2.4 Bone dynamics 
2.4.1 Bone structure and function 
The skeleton of an adult is composed of over 200 bones and cartilage. The skeleton 
provides structural support of the body, facilitates movements, protects internal organs, 
stores and releases minerals (e.g., calcium and phosphorus), and produces blood cells 
(i.e., hematopoiesis). The morphology of the bone can be viewed macroscopically and 
microscopically as seen in Figure 6. The outer layer of bone is coated by the highly 
innervated periosteum, which explains the pain-sensitivity of the tissue. Periosteum 
covers cortical bone, which constitutes about 80% of the skeletal mass. The structure of 
cortical bone is very dense and hard. Osteons are basic structural units of compact bone. 
They consist of concentric layers of calcified bone made by osteocytes, and a central 
canal, called the Haversian canal, that contains blood vessels, nerves, and lymphatics. 
The blood vessels of Haversian canal are interconnected with blood vessels on the 
surface of the bone. The lamellar structure of the osteons is due to arrangement of 
collagen fibrils. The endosteum membrane layer covers trabecular bone. This faces the 
medullary canal containing yellow bone marrow in long bones (Clarke, 2008; 
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Weatherholt et al., 2012). The volume of hematopoietic red bone marrow in bone 
cavities decreases with age and its replaced with yellow bone marrow filled with 
adipocytes (Takeshita et al., 2014). Trabecular bone is spongious, higher in surface area, 
less dense, and softer compared to cortical bone. It constitutes of about 20% of the bone 
mass, and it is found at both ends of long bones. The spongious structure called 
trabeculae, is due to a network of irregularly-shaped thin bars and broad plates. (Clarke, 
2008; Weatherholt et al., 2012).  
 
Figure 6. The macroscopic- and microscopic structures of long bone.  
Bone is constituted of minerals (50-70%), an organic matrix (20-40%), water (5-10%), 
and lipids (2-3%). The composition may vary according to the state of maturation and 
turnover, age, anatomic location, diet, and health (Boskey, 2013; Rey et al., 2009). The 
organic matrix contains only two to five percent of cells and five percent of water. 
Collagen, primarily type I collagen, constitutes 90% of the organic matrix of the bone. 
Osteocalcin, osteonectin, and osteopontin are non-collagenous proteins that promote 
mineralization and bone formation. Bone contains also different cytokines and growth 
factors, which are important for bone growth, turnover, cell activation, and 
differentiation. Hydroxyapatite crystals, which are calcium phosphate minerals, are the 
main inorganic mineral component of the bone. (Buckwalter et al., 1996; Florencio-
Silva et al., 2015; Wagermaier et al., 2006). 
2.4.2 Bone cells 
The main cell types of bone are osteoblasts, osteocytes, and osteoclasts. Osteoblasts and 
osteocytes are of mesenchymal origin, while osteoclasts are of hematopoietic origin 
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(Méndez-Ferrer et al., 2010). Macrophages are also hematopoietic in origin, and 
considered as a new class of bone cells interdependent with bone (Kaur et al., 2017). 
Osteoblasts have a single nuclei. They form bone and make up approximately five 
percent of all bone cells. Osteoblasts act in groups. They synthesize collagens, non-
collagenous proteins, such as osteonectin, osteopontin, and proteoglycans. Osteoblasts 
also express alkaline phosphatase (ALP). Osteoblasts take care of the bone 
mineralization by settling the hydroxyapatite crystals into collagen fibers (Caetano-
Lopes et al., 2007; Florencio-Silva et al., 2015). To contribute to the differentiation, 
activity, and survival of other cells and their own activity, osteoblasts produce different 
soluble factors, such as receptor activator of nuclear factor kappa β ligand (RANKL), 
the RANKL inhibitor osteoprotegerin (OPG), and macrophage colony stimulating factor 
(M-CSF). When osteoblasts are at the end of the bone formation cycle, they can go to 
apoptosis, become bone lining cells, or osteocytes (Crockett et al., 2011). The lifespan 
of osteoblasts is three months (Manolagas, 2000).  
Osteocytes are mature and permanent bone cells comprising most of the total amount of 
bone cells. Osteocytes have a lifespan of over 20 years. They are derived from bone-
forming osteoblast cells trapped in the bone matrix. However, they are different in 
morphology and function, because they lose a large part of their organelles (Aarden et 
al., 1994; Rochefort et al., 2010). They turn into dendritic-like cells with their long 
appendages, which they use as a net for communication with each other, and also with 
osteoblasts and bone lining cells (Bonewald, 2011). Osteocytes secrete RANKL, M-
CSF, and OPG, which further regulate the generation of osteoclasts (Bellido, 2014).  
Bone lining cells are also differentiated from osteoblasts, which have completed their 
bone-forming function. The morphology of these cells is flat and elongated, and they 
have flat nuclei. Bone lining cells cover the non-remodeled surface of the bone. The 
function of these cells is still unknown. However, it has been suggested that perhaps 
they regulate the osteoclast bone resorption by secreting collagenase to matrix, before 
osteoclasts can attach to the bone. These lining cells act through messages from 
osteocytes, which sense the need of bone remodeling. Thus, they are a major source of 
osteoblasts during adulthood. Especially, quiescent bone lining cells are suggested to 
differentiate into osteoblasts (Matic et al., 2016; Parfitt, 2001).  
Osteoclasts are large, highly polarized multinucleated cells with specialized 
morphological features (Teitelbaum, 2007). Multinucleated osteoclasts are the only cells 
that resorb the bone. They derive from a monocyte/macrophage lineage, differentiate 
towards an osteoclastic phenotype, and then fuse. Interestingly, mononuclear osteoclasts 
have been reported to have the ability to resorb the bone in vitro (Teitelbaum, 2007). 
Bone resorption needs a lot of energy, and osteoclasts have a high number of 
mitochondria (Williams et al., 1997). The lifespan of osteoclasts is two weeks 
(Manolagas, 2000). Numerous hormones and cytokines regulate osteoclast 
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differentiation and activity. However, the main regulator is RANKL//RANK/OPG 
signaling, where RANK binds to RANKL promoting osteoclast formation, activation, 
survival, and bone resorption. OPG inhibits osteoclast bone resorption by binding to 
RANKL (Boyce and Xing, 2008). Tartrate-resistant acid phosphatase 5b (TRACP) is an 
enzyme, which is a significant marker of osteoclasts. The biological function of TRACP 
is still unclear. However, it has been suggested that TRACP plays a role in bone 
resorption. Osteoclast transports degraded bone components through the cell with the 
help of transcytotic vesicles, where TRACP has been located. There are two forms of 
TRACP that circulate in human blood. TRACP 5a is derived from macrophages and 
dendritic cells, and TRACP 5b is derived from osteoclasts. TRACP 5b can be used for 
quantifying the number of osteoclasts (Halleen et al., 2006). C-terminal-crosslinked 
telopeptide of type I collagen (CTX) is a degradation product of type I collagen, which 
is released into the serum in vivo or medium in vitro after osteoclast bone resorption. 
CTX correlates with osteoclasts activity (Rissanen et al., 2008). In vitro, there are two 
important criteria for the definition of mature osteoclasts, such as the number of nuclei 
per cell (at least three) and TRACP activity (Kylmäoja et al., 2018; Minkin, 1982). 
2.4.3 Bone remodeling  
Bone remodeling is based on bone resorption by osteoclasts and bone formation by 
osteoblasts, and this process occurs throughout life. Most of the adult bone formation 
occurs after bone resorption. However, about three percent of bone forming occurs 
without resorption event and this is called bone modeling (Hattner et al., 1965; Ominsky 
et al., 2015). In addition, it has been shown that bone loading increases bone modeling 
(Ducher et al., 2005). The bone modeling and remodeling is regulated by local and 
systemic factors, and an imbalance in these processes could lead to bone loss and 
further to severe diseases, such as osteoporosis (Eriksen, 2010) or osteopetrosis. During 
the bone remodeling process, osteoclasts and osteoblasts form a basic multicellular unit 
(BMU), the organization of which differs in cortical and trabecular bone. On trabecular 
bone, osteoclasts travel approximately 25 µm each day, and they resorb the bone by 
making a trench with a depth of 40-60 µm. Trabecular bone is remodeled more 
dynamically than cortical bone. Almost five percent of cortical bone is remodeled every 
year. In cortical bone, osteoclasts resorb a cylindrical tunnel with a size of 2000 µm 
long and 200 µm wide in the bone with a speed of 20-40 µm per day. Thus, the BMU 
unit maintains its size for many months despite of short-lived osteoclasts, which are 
replaced then with new ones. Finally, the tunnel is fulfilled by thousands of osteoblasts 
that rebuild the bone (Parfitt, 1994). 
The resorption process starts, when mononuclear preosteoclasts migrate to the bone 
surface, and they fuse to a group of multinucleated osteoclasts. Before that, osteocytes 
31123633_Vaitoskirja_Paula_Pennanen_Laaketiet_tdk_sisus_B5_1705.indd   29 17.5.2019   8.20
30 Review of literature 
send signals through osteoblasts and bone lining cells for the need of resorption of old 
bone. Mononuclear preosteoclasts fuse and activate to mature osteoclasts with the help 
of RANKL/RANK signaling by these other bone cells (Boyce et al., 2012). Bone lining 
cells prepare the bone surface for osteoclast resorption by secreting collagenases 
(Parfitt, 2001). Bone resorption can start, when an osteoclast attaches directly and 
indirectly to bone surface with the help of transmembrane molecules CD44 and aVβ3 
integrin and intracellular proteins, such as talin, vinculin, and F-actin (Deguchi et al., 
2016). After attachment to the bone, the osteoclast polarizes and forms four different 
membrane domains: the sealing zone and a ruffled border underneath the osteoclast, a 
functional secretary domain (FSD) on top of the cell, and a basolateral membrane. 
Osteoclast degrades mineralized bone matrix by dissolving crystalline hydroxyapatite 
and proteolytic cleavage of the organic matrix, which includes collagen. The organic 
matrix is degraded with several proteolytic enzymes. The degraded products are 
removed via osteoclasts by transcytotic vesicles and released into extracellular space. 
Osteoclast bone resorption releases bone minerals, such as calcium into the 
bloodstream, which is very important for calcium regulation balance of the body. 
Finally, osteoclast returns to the non-resorbing area, or undergoes an apoptosis 
(Väänänen et al., 2000). 
2.5 Osteoclasts  
2.5.1 Osteoclasts domains 
An osteoclast is an effective machine to resorb the bone. To enable this process, the 
osteoclast attaches to the bone with a specialized actin-rich structure known as the 
sealing zone (SZ). Attachment of osteoclasts to the bone surface is mediated via integrin 
receptors involved in cell-cell and cell-matrix adhesions: αVβ3 (vitronectin receptor), 
α2β1 (collagen receptor), αVβ1, and αVβ5. Specially, αVβ3 is highly expressed in 
osteoclasts, and it plays a key role in the formation of the SZ. The inhibition of αVβ3 
reduces bone resorption without changing the number of osteoclasts (Lakkakorpi et al., 
1993; Nakamura et al., 1999; Nesbitt et al., 1993). The SZ forms a tightly isolated area 
between the ECM and osteoclast cell membrane. Formation of SZ is followed by 
osteoclast polarization resulting in three different membrane domains. One of the 
domains of polarized osteoclast is the basolateral membrane, which is not in contact 
with mineralized bone matrix. It is important in cell-cell contacts, because different 
proteins and receptors needed in cellular contacts are seen there, such as vitronectin 
receptors and connexin-43. Connexin forms gap junctions between osteoclasts, and gap 
junctions are needed for diffusion of small metabolites, growth factors, ions, other 
molecules, and nutrients (Giepmans and van Ijzendoorn, 2009; Ilvesaro and Tuukkanen, 
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2003). The osteoclast forms a long finger-like structure, which is a highly ruffled 
membrane structure underneath the cell and which faces the bone. The space between 
the ruffle border and bone is called Howship’s lacuna. The bone mineral is resorbed at 
low pH, created by secretion of hydrochloric acid by the vacuolar H+-ATPase. 
Cathepsin K is sectered from osteoclasts to the resorption space under the cell, and it 
secretes the bone organic matrix, mainly type I collagenase (Troen, 2004; Väänänen et 
al., 1990). The ruffled border is responsible for a bidirectional pathway, which includes 
substances that resorb the bone, and uptake and transcytosis of bone degradation 
products. The degraded bone matrix is transferred inside the cell, which are endocytosed 
in transcytotic vesicles and are moved to the top of the osteoclast toward the plasma 
membrane’s functional secretory domain. The degraded bone matrix is released there 
into the extracellular base (Itzstein et al., 2011; Mulari et al., 2003). These domains will 
disappear, when osteoclasts have done the resorption and detach from the bone. 
2.5.2 The cytoskeleton of osteoclasts 
The cytoskeleton of the eukaryotic cell is composed of proteins cables, which are 
located all over the cell cytoplasm organized into a network. The cytoskeleton of 
osteoclasts undergoes highly dynamic changes to enable the changes in cell shape, 
invasion, migration, correct positioning of the organelles, cellular contacts and 
intracellular membrane transport. There are three main types of filaments of 
cytoskeleton: intermediate filaments, microtubules, and microfilaments (Fletcher and 
Mullins, 2010).  
Intermediate filaments are composed of a variety of proteins, such as vimentin. The 
main function of intermediate filaments is to provide mechanical stability and structural 
support to the cell (Watanabe et al., 1995; Wilson, 2011). Microtubules are highly 
dynamic structures, whose main functions are to support the cell structure, but they are 
also involved in the transport of material within cells (Fletcher and Mullins, 2010; 
Goldstein and Yang, 2000). It has been shown that inhibition of microtubules interfere 
with osteoclast podosome belt formation (Ti et al., 2015). 
Actin is the main component of microfilaments. Bone resorption and the actin ring are 
the hallmarks of osteoclasts. The basic structure of dynamic actin is monomeric 
globular actin (G-actin), which polymerizes to helical F-actin. The structure of two-
stranded helical polymer F-actin filaments is formed, when the two polymerized F-actin 
chains are bound side-by-side with an equivalent binding between monomers. Actin 
filaments are abundant components of the cytoskeleton and composition for many 
cellular structures, and actin determines the shape and movement of the cell (Gurel et 
al., 2014). Highly branched actin filaments support and build up the forces, which are 
needed in either motility or interaction with other cells like osteoclasts (Pollard and 
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Borisy, 2003). The existence of many actin binding or actin-related proteins, which can 
cross-link to actin filaments, controls a highly organized, bundled, and branched 
composition of the actin network (Fletcher and Mullins, 2010). The actin network is 
continuously remodeled, assembled, and disassembled, e.g., by severing, capping, or 
depolymerizing the filaments (Zalli et al., 2016). Tyrosine kinase c-Src controls actin 
filament rearrangement and remodeling, thus, it plays multiple roles in integrin 
signaling (Destaing et al., 2008). The disruption of c-Src gene in mice results in 
osteopetrosis suggesting a role of the c-Src in osteoclast function, especially for cell 
attachment to the bone (Miyazaki et al., 2004). Cortactin is a substrate of c-Src, and it 
plays a role in actin polymerization and rearrangement. Numerous proteins, such as 
cortactin, activate actin-related protein 2/3 (Arp2/3) complex into actin filaments 
stabilizing actin branching. The Arp2/3 complex forms branched actin filaments with a 
70ᴼ angle to existing actin filament, so that new filaments can grow to old ones (Mullins 
et al., 1998). To save the actin network dynamic structure, cofilin severs and triggers the 
twist of actin filaments (McGough et al., 1997; Pavlov et al., 2007).  
In osteoclasts, the actin cytoskeleton is different according to their substratum, such as 
on glass, or on bone. On glass, actin forms a podosome belt, which is surrounded by a 
loose actin cloud, on the substratum level of the cell. The actin cloud is organized by 
αVβ3 integrin among other proteins. Podosomes are short-lived actin-rich structures 
found usually in the periphery of the cell that contain other proteins, such as WASP, 
Arp2/3, CD44, cortactin, and gelsolin. They are needed for cellular adhesion, 
movement, and invasion. Actin-rich podosome structures change during osteoclast 
differentiation and activation. First, podosomes are organized as clusters and then into 
short-lived rings. When maturation occurs, these structures turn into a podosome belt on 
the cell periphery, and finally into a sealing zone to ensure the bone resorption. 
Podosomes are packed densely in the SZ. Formation of the SZ requires also the 
interaction of microtubules, cofilin, and cortactin (Saltel et al., 2008; Zalli et al., 2016). 
Multiple nuclei and specific actin structures are associated with osteoclasts. 
Interestingly, actin filaments play a role in nuclei movement. It has been shown that 
both tubulin and actin play also a role in nuclei positioning. Nuclei are located in special 
regions or evenly inside of the cell. The location of the nuclei are carefully arranged, 
especially when there are syncytial nuclei inside the cell (i.e.,multinucleated cells) (Starr 
and Han, 2003). Therefore, actin may have an important role in nuclear positioning. 
Actin filaments are also needed to anchor the nuclear envelope with different proteins, 
e.g., Anc-1. Nuclear positioning is poorly understood. However, impaired nuclear 
positioning is known to lead to various diseases such as progeria or myopathies 
(Gundersen and Worman, 2013).  
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2.5.3 Fusion and contacts of osteoclasts in vitro 
Cell fusion is an important but exceptional process in the body. Cell fusion is needed 
during fertilization, muscle differentiation, and fusion of monocyte progenitors into 
osteoclasts. The first step of cell fusion is to find the fusion partner and to have cell-to-
cell contact, which leads to local membrane deformations and further to dynamic 
changes of lipid bilayers (Chernomordik and Kozlov, 2008). Effective bone resorption 
needs multinucleated osteoclasts, however, the mechanism in the fusion process is still 
unknown. Recent studies have shown that osteoclast fusion needs a fusion acceptor cell 
and fusion donor cell. Four different kinds of cell fusion have been shown. Prior to 
fusion, cells can make on broad membrane contact with each other, one cell can take the 
other cell in a phagocytic cup, cells can contact each other with a narrow tube, or one 
cell goes on top of the other cell just before fusion (Søe et al., 2015). In addition, 
mononucleated cells can fuse with multinucleated cells, or two multinucleated cells can 
fuse together. More mature osteoclasts prefer to fuse with less mature osteoclasts (Søe 
et al., 2015). Osteoclast fusion can also happen through two different types of cell 
contacts. When cells are in broad membrane contact, small preosteoclasts fusion is 
mediated by the membrane protein CD47. In addition, the membrane protein CD43 and 
syncytin-1 promote the fusion of multinucleated osteoclasts (Hobolt-Pedersen et al., 
2014; Møller et al., 2017).  
Cellular crosstalk is essential for osteoclast fusion. Gap junctions are hydrophilic 
intercellular channels formed by connexin proteins. These channels are needed for 
osteoclast differentiation, diffusion of ions, exchange of nutrients, metabolites, and 
small soluble molecules (Schilling et al., 2008). Inhibition of gap junctions in mouse 
bone marrow cultures decreases the differentiation of osteoclasts and bone resorption 
(Kylmäoja et al., 2013). Membrane tunneling nanotubes (TNTs) are F-actin rich 
structures that bridge from cell to cell without touching the substratum. TNTs are 50-
200 nm in diameter and can connect to cells even over long distance. These tunnels 
enable rapid transport for membrane vesicles, organelles, and small molecules (Gerdes 
and Carvalho, 2008; Rustom et al., 2004). TNTs have a role in cell metabolism by 
transferring calcium ions from cell to cell. Many different cell types form TNTs 
enabling cellular contact and exchange of signals even from distant cells (Dupont et al., 
2018). Osteoclast precursors form TNTs while searching a fusion partner, and TNTs 
disappear prior to fusion. Inhibition of the formation of TNTs with latrunculin B 
decreases the fusion of mononuclear cells into osteoclasts (Takahashi et al., 2013). Two 
different methods have been observed to lead to TNT formation. A protrusion of a cell 
elongates, until it reaches a neighboring cell, which may lead to membrane fusion. TNT 
may also form when two cells in contact move apart and leave an intercellular nanotube 
between the cells (Davis and Sowinski, 2008). 
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2.5.4 Signaling in osteoclastogenesis 
There are several studies exploring osteoclastogenesis-related signaling pathways. 
However, they have mostly been explored with rodent cells. Osteoclastogenesis is 
stimulated by two different molecules called M-CSF and RANKL that originate from 
osteoblasts and other bone cells. M-CSF binds to c-Fms receptor and RANKL binds to 
RANK receptor on the cell membrane, and they stimulate crucial signaling pathways in 
osteoclastogenesis involved in differentiation, activation, function, and survival of 
osteoclasts (Kim and Kim, 2016). Osteoclast signaling is a highly complex system that 
is not fully understood. Many skeletal diseases are due to an increased number of 
osteoclasts, or impaired osteoclast functions. Therefore, there is a need to increase the 
understanding of osteoclast signaling. This study concentrates to understand the role of 
Ras/Raf/MEK/ERK, PKC, PI3K/Akt/mTOR, and p38 MAPK signaling pathways in 
osteoclast differentiation (Figure 7).  
 
Figure 7. Signaling pathways in osteoclastogenesis. 
M-CSF/c-Fms complex is known to activate downstream signals such as MEK/ERK 
and PI3K/Akt. RANKL binding to RANK receptor activates tumor necrosis factor 
receptor-associated proteins (TRAFs), especially TRAF6, which transmits the signal to 
several different downstream targets such as MEK/ERK, PI3K/Akt, and mitogen-
activated protein kinase p38 (p38 MAPK) among other pathways (Kim and Kim, 2016).  
Ras plays a central role in cell signaling, and its activity is regulated with more than 170 
Ras-related proteins. Monomeric small guanosine triphosphatases (GTPases) belong to 
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the proteins of a Ras superfamily, and they can hydrolyze active GTP into inactive 
GDP, which further influences on the Ras activity (Colicelli, 2004). Guanine nucleotide 
exchange factors (GEFs) and GTPase-activating proteins (GAPs) regulate the activity of 
GTPases, as GEFs catalyze GDP into GTP and GAPs hydrolyze GTP into GDP (Bos et 
al., 2007). The osteoclast adhesion to bone is dependent on the activity of the GTPases 
and, therefore, the signaling of Ras (Itzstein et al., 2011). NF1 tumor-suppressor gene 
protein neurofibromin down-regulates the activity of Ras. Mutation in the NF1 gene is 
known to result in hyperactive osteoclasts (Heervä et al., 2010). A gain-in-function of 
NF1 osteoclasts leads to increased bone resorption (Heervä et al., 2010; Rauen et al., 
2015). Ras has many downstream targets, and the main pathways are 
Ras/Raf/MEK/ERK (MAPK pathway) and the Ras/PI3K/Akt/mTOR (Chappell et al., 
2011). Ras activity is needed in every phase of the cell cycle (Castellano and 
Downward, 2011). Farnesyl thiosalisylic acid (FTS) is a well known inhibitor of Ras 
inhibiting all isoforms of it (Laheru et al., 2012). The few available studies related to 
inhibition of Ras on osteoclastogenesis show that inhibition of Ras decreases the 
number of mononuclear cells and rodent osteoclast survival (Aizman et al., 2014; 
Bradley et al., 2008). 
MEK/ERK signaling belongs in the cascade of the MAPK family. MEK/ERK signaling 
can be activated by M-CSF and RANKL to promote osteoclast survival (Bradley et al., 
2008; Kim and Kim, 2016). Phosphorylation of ERK1 and ERK2 (also known as 
p42/p44 MAPK) by MEK increases their enzymatic activity (Zhang and Liu, 2002). 
MEK1/2 is the only known activator of ERK1/2 (Favata et al., 1998). Therefore, 
specific MEK inhibitors can be used to understand the basic mechanism behind 
MEK/ERK signaling in cells. PD98059 and UO126 are inhibitors affecting the 
activation of MEK1/2 (Favata et al., 1998). The effect of these inhibitors toward rodent 
osteoclast differentiation is contradictory. However, most studies have shown that 
inhibition of MEK decreases osteoclast differentiation (Amano et al., 2015; Breitkreutz 
et al., 2007; Hotokezaka et al., 2002). 
In addition to MEK/ERK1/2, osteoclast cell differentiation and function is regulated 
through another MAPK called p38 MAPK (Thouverey and Caverzasio, 2015). There 
are four isoforms of p38 MAPK (α, β, γ and δ). It has been shown that osteoclasts and 
their precursors express at least p38α (Böhm et al., 2009). BIRB796 inhibits all 
isoforms of p38, whereas, SB203580 inhibits α and β isoforms of p38 MAPK (Kuma et 
al., 2005; Yong et al., 2009). Studies have reported that inhibition of p38 MAPK 
decreases the number of rodent osteoclasts (Li et al., 2002; Matsumoto et al., 2000).  
The lipid PI3K is involved in cellular growth, proliferation, and survival. It is composed 
of two different subunits. The first one is the lipid kinase catalyzing subunit p110, and 
the other one is p85, which regulates the p110 activity (Ponzetto et al., 1993). PI3K 
phosphorylates lipid phosphatidylinositol-4,5-bisphosphate (PIP2) and generates it into 
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the lipid second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), which can 
activate several downstream targets (Luo et al., 2003; Miao et al., 2010). In the M-
CSF/c-Fms complex, the tyrosine residue of Y-559 activates c-Src that further activates 
PI3K and Akt pathway (Kim and Kim, 2016) Both Ras and PI3K are needed in the cell 
cycle to activate the cells from the G0 into the G1 phase (Castellano and Downward, 
2011). Osteoclasts originate from hematopoietic cells. Zebrafish studies have shown 
that Ras/PI3K/Akt signaling is a key regulator of hematopoiesis (Liu et al., 2008). 
Interestingly, studies with hematopoietic progenitors suggest crosstalk between the 
PI3K and MAPK pathway. PI3K can activate Raf and further the downstream signaling 
Raf/MEK/ERK through Ras by an unknown mechanism (Wandzioch et al., 2004). PI3K 
is known to associate with αVβ3 and Src in osteoclasts (Hruska et al., 1995). Inhibition 
of PI3K inhibits formation of F-actin structure and further osteoclast attachment on 
bone and plastic, suggesting that PI3K plays a role in osteoclast actin cytoskeleton 
formation (Lakkakorpi et al., 1997). Inhibition of PI3K with the inhibitor LY294002 
decreases osteoclast number in rodent cells (Bradley et al., 2008). 
 mTOR kinase is a member of PI3K-related kinase family, and it regulates cell growth 
and metabolism. There are two different mTOR complexes: mTOR1 and mTOR2. 
Regulatory-associated protein of mTOR1 is called raptor, and it is essential for the 
activity and regulation of mTOR kinase. The regulatory-associated protein in mTOR2 is 
called rictor (Laplante and Sabatini, 2009). The mTOR interacts with MAPK and 
PI3K/Akt pathways, and inhibition of mTOR in patients with metastatic disease 
activates Ras/MAPK pathway (Carracedo et al., 2008). Inhibition of mTOR with an 
inhibitor of rapamycin decreased the amount of TRACP-positive rodent osteoclasts and 
TRACP activity of the cells, suggesting that mTOR1 plays a crucial role in osteoclast 
differentiation (Dai et al., 2017).  
Protein kinase C (PKC) is a lipid-sensitive enzyme that has many roles in cell 
proliferation, differentiation, and survival in cells (Dekker and Parker, 1994). PKC is 
activated by growth factor receptors. PKC activates phospholipase C (PLC), which 
further hydrolyzes PIP2 (Steinberg, 2008). Ca2+-dependent PKC represents a classical 
group of  isoforms of PKC: α, β, and γ isoforms (Kohout et al., 2002). PKC has been 
linked to osteoclast differentiation and formation. Inhibition of PKCβ decreased the 
number of TRACP positive mouse osteoclasts and suppressed ERK/MEK activation 
suggesting a role of PKCβ in osteoclast differentiation and MEK/ERK signaling 
pathway (Lee et al., 2003). The PKC-specific inhibitor GÖ6976 inhibits isoforms of α 
and β, and is an effective small molecule drug in cell cultures (Bailey et al., 2014; 
Koivunen et al., 2004). 
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3 AIMS OF THE STUDY 
1. To investigate the effect of sex hormones on Schwann cells cultured from 
cutaneous neurofibromas and having one or two hits of the NF1 gene.  
2. To investigate the actin structure of peripheral blood-derived human osteoclasts 
on glass surfaces with confocal and STED microscopies. 
3. To study the human osteoclast differentiation pathways in mononuclear cell 
progenitors from healthy persons and from patients with NF1. 
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4 MATERIALS AND METHODS 
This chapter summarizes materials and methods used in this study. More detailed 
descriptions are available in the original publications (I-III). 
4.1 Ethical approval, permissions, and samples 
This study has been performed in accordance with the Declaration of Helsinki and 
approved by the Ethics Committee of Southwest Finland Hospital District, Turku, 
Finland. Participants gave their informed written consents to osteoclasts and Schwann 
cell cultures. Blood samples from healthy persons were obtained from the personnel of 
Institute of Biomedicine, University of Turku. Blood samples and fresh neurofibroma 
tissues were obtained from the Department of Dermatology from Turku University 
Hospital. The study was carried out at Turku University Hospital and the University of 
Turku. 
4.2 Schwann cell cultures from human neurofibromas (I) 
NF1 patient’s cutaneous neurofibromas were removed with a CO2 laser and immersed 
immediately into RPMI medium (Gibco, Grand Island, NY, Cat. No. 21870-076). 
Neurofibromas were cut into small pieces and immersed for 3-7 days in preincubation 
medium shown in Table 1. 
Table 1. Preincubation medium of the neurofibromas. 
Reagent name Concentration Source Cat. No. 
DMEM, high glucose (4.5g/l) 89% Gibco, Grand Island, NY 41966-029 
FBS, USA origin 10% Gibco, Grand Island, NY 16000-044) 
Penicillin-Streptomycin 1% (100 
µg/ml) 
Gibco, Grand Island, NY 15140-122 
Amphoterecin B 1.25 µg/ml Gibco, Grand Island, NY 15290-018 
Forskolin 2 µmol/l Merck, Darmstadt, Germany 344270 
Thereafter, a neurofibroma was dissociated enzymatically with preincubation medium 
shown in Table 2 and mechanically with pipette tips.  
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Table 2. Enzymatic dissociation medium of the neurofibromas. 
Reagent name Concentration Source Cat. No. 
DMEM, high glucose 
(4.5g/l) 
89% Gibco, Grand Island, NY 41966-029 
FBS, USA origin 10% Gibco, Grand Island, NY 16000-044) 
Penicillin-Streptomycin 1% (100 µg/ml) Gibco, Grand Island, NY 15140-122 
Collagenase 160 U/ml Merck, Darmstadt, 
Germany 
234153 
Dispase I 0.8 U/ml Roche, Indianapolis, 
Indiana, USA 
04942086001 
Cell culture plastics were coated for Schwann cell cultures with poly-L-lysine and 
laminin, which is shown in Table 3. 
Table 3. Poly-L-lysine and laminin coating. 
Reagent name Concentration Source Cat. No. 
Poly-L-lysine 1 mg/ml Sigma-Aldrich, ST Louis, MO P-1524 
Laminin 1 mg/ml Gibco, Invitrogen, Grand Island, 
NY 
23017-015 
Half of the gained cell suspension from neurofibroma was plated in NF1+/- medium to 
enrich NF1+/- Schwann cells. The other half was treated for 24 hours with medium 
containing forskolin (NF1+/- medium, Table 4) followed by serum-free medium (Table 
5) for 24 hours, and finally in proliferation medium without forskolin (NF1-/- medium as 
shown in Table 4 to gain NF1-/- Schwann cells). 
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Table 4. NF1+/-  and NF1-/- Schwann cell proliferation medium. 
Reagent name Concentration Source Cat. No. 
DMEM, high glucose (4.5g/l) 89% Gibco, Grand Island, NY 41966-
029 
FBS, USA origin 10% Gibco, Grand Island, NY 16000-
044) 
Penicillin-Streptomycin 1% (100 
µg/ml) 
Gibco, Grand Island, NY 15140-
122 
3-isobutyl-1-methyl xanthine 
(IBMX) 
0.5 mM Sigma-Aldrich, St.Louis, 
MO 
I-5879 
Beta 1-heregulin 10 nM Peprotech, Rocky Hill, NJ 100-03 
Insulin 2.5 µg/ml Sigma-Aldrich, St.Louis, 
MO 
I-0516 
Forskolin* 0.5 mM Merck, Darmstadt, 
Germany 
344270 
*NF1-/- Schwann cells were cultured in medium without forskolin with the exception 
when NF1-/- Schwann cells were looking unhealthy or cells were divided, forskolin was 
added to the medium for the first day.   
Table 5. N2-supplement medium to gain NF1-/- Schwann cells. 
Reagent name Concentration Source Cat. No. 
DMEM, high glucose (4.5g/l) 73% Gibco, Grand Island, NY 41966-029 
F12-medium 25% Gibco, Grand Island, NY 11765-054 
Penicillin-Streptomycin 1% (100 µg/ml) Gibco, Grand Island, NY 15140-122 
N2-supplement 1% Gibco, Grand Island, NY 17502-048 
IBMX 0.5 mM Sigma-Aldrich, St. Louis, 
MO 
I-5879 
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4.3 Incubation of Schwann cells with sex hormones 
The effect of sex hormones on human NF1+/- and NF1-/- Schwann cell proliferation was 
quantified with a 5-bromo-2-deoxyuridine (BrDU) colorimetric enzyme-linked 
immunosorbent assay (ELISA). 6000 cells per well of passage 5 or greater Schwann 
cells were plated on coated 96-well plates in proliferation medium without forskolin and 
in colorless DMEM (Gibco, Cat. No 31053-028). Sex hormones shown in Table 6 were 
added at day 0 at concentrations of 0.001-100 nM for 48 or 96 hours. Absorbance at 450 
nm was measured to determine BrDU corporation of the cells. 
Table 6. Reagents and equipment of Schwann cell proliferation study with sex 
hormones. 
Reagent name Source Cat. No 
Estradiol Sigma-Aldrich, St. Louis, MO E2758 
Testosterone Sigma-Aldrich, St. Louis, MO 86500 
hCG Sigma-Aldrich, St. Louis, MO C0684 
BrDU Roche Diagnostics, Mannheim, Germany 11647229001 
Blocking reagent for BrDU 
Assay 
Roche Diagnostics, Mannheim, Germany 11647229001 
Hidex microplate reader, The Plate Chameleon Multilabel Counter, Hidex Oy, Turku, 
Finland 
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4.4 Imaging and immunohistochemistry (I-III) 
4.4.1 Microscopy 
Table 7. Microscopes used in cell imaging 
Microscope Used in study 
Carl Zeiss AxioImager M1 microscope equipped with AxioCam ICc3 
camera, Carl Zeiss Zen 2012 (blue edition) software and Image J 1.49 
software 
I, III 
Leica TCS SP5 Confocal microscope equipped with photomultiplier 
tubes as detectors, LAS AF software and Image J 1.49 software II, III 
Leica TCS SP5 STED equipped with MaiTai HP, LAS AF software and 
Image J 1.49 software II 
In addition, images were further processed into collages with CorelDraw X7. 
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4.4.2 Antibodies and fluorescent compounds 
Table 8. List of antibodies and fluorescent compounds. 
Reagent name Source 
Cat. No Used 
in 
study 
Atto-647N Phalloidin Sigma-Aldrich, St. Louis, MO 65906 II 
Alexa-Fluor 488 Phalloidin Molecular Probes, Eugene, OR A12379 II 
Hoechst 33342 Molecular Probes, Eugene, OR H3570 II, III 
Rabbit mab to human/mouse 
c-Src  
Cell Signaling Technology, 
Danvers, MA 
2109 
II 
Mouse mab to human/mouse 
cortactin 
Santa Cruz, Biotechnology, Santa 
Cruz, CA 
55579 
II 
Rabbit pab to human/mouse 
anti-arp2 Abcam, Cambridge, UK 
ab47654 
II 
Mouse mab to human/mouse 
cofilin 
Santa Cruz, Biotechnology, Santa 
Cruz, CA 
53934 
II 
Alexa-Fluor 488-conjugated 
goat anti-mouse IgG Abcam, Cambridge, UK 
ab150113 
II 
Alexa-Fluor 488-conjugated 
goat anti-rabbit IgG Molecular Probes, Eugene, OR 
A11008 
II 
Dil, 1,1'-Dioctadecyl-3,3,3',3'-
Tetramethylindocarbocyanine 
Perchlorate 
Life Technologies, Carlsbad, CA 
V22889 
II 
Quant-iT™ PicoGreen® 
dsDNA Reagent Life Technologies, Carlsbad, CA 
P7581 
II 
Abberior Phalloidin 
conjugated STAR635 Abberior, Göttingen, Germany 
2-0205-
002-5 
II, III 
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4.5 Human peripheral blood mononuclear cell differentiation into 
osteoclasts (II, III) 
Briefly, the mononuclear cells were collected with Ficoll-Paque PLUS (GE HealthCare 
Bio-Sciences, Uppsala, Sweden) centrifugation from fresh blood samples of healthy 
persons and NF1 patients. Then cells were counted with Bürker-Türk counting chamber, 
half million cells were seeded on glass coverslips (12 mm round, thickness of 0.17 mm 
Marienfeld GmbH & Co.kG, Germany) or bone slices on 96-well plate (Purchased from 
Pharmatest Services Ltd., Turku, Finland) and differentiated to multinuclear osteoclasts 
in the presence of medium given in Table 9. Half of the medium was replaced with 
fresh medium every 3-4 days. Cells were cultured on glass coverslips for 8-10 days (II) 
or 4-5 days (III) and on bone slices for 16 days (III).  
Table 9. Medium composition for human osteoclasts differentiation. 
Reagent name Concentration Source Cat. No. 
AlphaMEM 89% Gibco, Grand Island, NY 41061-029 
Inactivated Fetal bovine 
serum, USA origin, iFBS 10% 
Gibco, Grand Island, NY 
16000-044) 
Penicillin-Streptomycin 1% (100 µg/ml) Gibco, Grand Island, NY 15140-122 
Recombinant Human 
sRANK Ligand, RANKL 20 ng/ml 
Peprotech, Rocky Hill, 
NJ 310-01 
Macrophage Colony 
Stimulating Factor, M-CSF 10 ng/ml 
Peprotech, Rocky Hill, 
NJ 300-25 
4.6 Human peripheral blood mononuclear cell differentiation into 
macrophages (II) 
To prepare macrophage culture, the mononuclear cells were collected with Ficoll-Paque 
PLUS centrifugation from fresh blood samples of healthy persons. Cells were counted 
and half million cells were seeded on glass coverslips in a serum-free medium, allowed 
to settle for two hours, and then washed to remove non-adherent cells. Thereafter, cells 
were cultured for 7 days with macrophage medium shown in Table 10. 
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Table 10. Macrophage culture medium. 
Reagent name Concentration Source Cat. No. 
AlphaMEM 89% Gibco, Grand Island, NY 41061-029 
Inactivated Fetal bovine 
serum, USA origin, iFBS 10% 
Gibco, Grand Island, NY 
16000-044) 
Penicillin-Streptomycin 1% (100 µg/ml) Gibco, Grand Island, NY 15140-122 
Macrophage Colony 
Stimulating Factor, M-CSF 10 ng/ml 
Peprotech, Rocky Hill, 
NJ 
300-25 
4.7 Inhibitors used to study osteoclast differentiation pathways (III) 
Table 11. Summary of inhibitors. (Modified from the original publication III.) 
Inhibitor Source Target of the inhibitor Concentration Cat. No. 
Vehicle 
+DMSO - Control 0.05% - 
FTS 
Cayman chemical 
company, Ann Arbor, MI, 
USA 
All isoforms of 
Ras  10 µM 1001051 
GÖ6976 Calbiochem, San Diego, CA, USA PKC α, β 0.01 µM 365250 
U0126 Cell Signaling, Danvers, MA, USA MEK 0.1 µM 9903S 
PD98059 Calbiochem, San Diego, CA, USA MEK 1 µM 513000 
LY294002 Cell Signaling, Danvers, MA, USA PI3K α, δ, β 1 µM 9901S 
Rapamycin Cell Signaling, Danvers, MA, USA mTOR 0.001 µM 9904S 
BIRB796 
Axon, Medchem BV, 
Croningen, the 
Netherlands 
p38 α, β, γ, δ 10 µM 1358 
SB203580 Calbiochem, San Diego, CA, USA P38 α, β 1 µM 559389 
4.8 Other used methods (I-III) 
Table 12 summarizes other methods used in the original publications, where they have 
been described in detail. 
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Table 12. The methods used in the original publications (I-III). 
Method Used in study 
Specific TRACP protein staining II, III 
Immunohistochemical labeling I-III 
Western blotting III 
Carboxy-terminal collagen crosslinks (CTX) measurement III 
Image analysis I-III 
4.9 Statistical analysis 
Table 13. The statistical methods used in the original publications (I-III). 
Statistical method Used in study 
Linear-mixed effects regression with random intercepts I, III 
Statistical software R version 3.3.2 with ImerTest package version 2.0-
33 
I 
Statistical software R version 3.3.0 with ImerTest package version 2.0-
32 and Ime4 (Version 1.1-12) 
III 
Linear mixed effects models with Poisson distribution with nested 
random intercepts 
III 
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5 RESULTS AND DISCUSSION 
5.1 Culturing of NF1+/- and NF1-/- Schwann cells from human 
neurofibroma 
The method for culturing NF1+/- and NF1-/- Schwann cells from human neurofibromas 
was established by Serra et al. (Serra et al., 2000). Our results showed that relatively 
small (Ø 5-15 mm) neurofibromas were optimal sources for cultures when considering 
the growth potential of Schwann cells. These cells were cultured in DMEM containing 
phenol red, knowing that phenol red is similar to estrogen and binds ERs of the cells 
(Berthois et al., 1986; Welshons et al., 1988). When NF1+/- and NF1-/- Schwann cells 
were cultured in colorless DMEM, the cells proliferated slower, and the viability of the 
Schwann cells decreased. Thereafter, the Schwann cells were decided to let proliferate 
in red DMEM, but the hormone studies were carried out in colorless DMEM. Our 
results showed that culturing Schwann cells from neurofibromas is a very delicate 
process. Culturing the cells without serum, which always contains small amounts of 
hormones, was not feasible because the cells did not survive. The used culturing 
protocol for Schwann cell cultures from human neurofibromas separated two genetically 
different Schwann cells populations, which were even shown by examining the 
morphology of the cells. NF1+/- Schwann cells were dense, formed linear bundles, and 
swirls, while NF1-/- Schwann cells were homogenous and were a typical spindle-shaped 
cell.  
The crucial difference between NF1+/- and NF1-/- Schwann cell cultures was the 
presence or absence of forskolin in the proliferation medium. Forskolin was used 
continuously in NF1+/- Schwann cell cultures. However, NF1-/- Schwann cells needed 
forskolin momentarily to stimulate the cell proliferation after passaging the cells by 
trypsinization or when cells looked non-viable. It seems that neurofibromin reduces 
cAMP and cyclin D1 in Schwann cells (Kim et al., 2001), and in turn, Ras-deficient 
NF1-/- Schwann cells have increased levels of cAMP and cyclin D1, which it maintains 
by itself with an unknown mechanism and without the continuous need of forskolin.  
Schwann cell cultures, especially NF1+/- cultures, contain a lot of fibroblasts. To 
achieve pure Schwann cell cultures free of fibroblasts is possible by using different 
growth factors and passaging the cells repeatedly. It is known that fibroblast 
proliferation is inhibited by cAMP. Thus, IBMX together with forskolin has become a 
useful tool to inhibit the growth of fibroblasts (Espinoza and Wharton, 1986; Roberts et 
al., 2018).  
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5.2 The effect of estradiol on the proliferation of NF1+/- and NF1-/- 
Schwann cells 
NF1 is a hormone-dependent disorder. Cutaneous neurofibromas arise during puberty 
and increase in number and size during pregnancy (Dugoff and Sujansky, 1996; Xiong 
et al., 2015). Estradiol is needed for pubertal growth. Before puberty begins, estradiol 
levels are low. The release of GnRH from GnRH neurons in pulses leads to activation 
of the pituitary ovarian axis and secretion of LH and FSH hormones and further to 
estrogen stimulation in ovaries, which initiates puberty in girls around the age of 8 years 
old (Herman-Giddens et al., 1997; Ojeda et al., 2010). Estrogen concentrations can vary 
widely during the menstrual cycle (Veldhuijzen et al., 2013). The levels of estradiol 
increase during early pregnancy and continue to play an important role in maintaining 
the pregnancy (Albrecht and Pepe, 2010). Since the estrogen levels and neurofibromas 
increase during the timespan of puberty and pregnancy, it leads to a hypothesis that 
estradiol influence on neurofibroma tumor formation. Since neurofibromas consist 
mainly of Schwann cells, we characterized the effect of estradiol on the proliferation of 
NF1+/- and NF1-/- Schwann cells. 
The results showed that genotype influences the response of Schwann cells to steroid 
hormones. The effect of estradiol on the proliferation of human NF1+/- and NF1-/- 
Schwann cells after two days with concentrations of 0.001-10nM had no consistent 
effect compared to the vehicle control. However, estradiol increased significantly, to 86-
99% NF1-/- Schwann cell proliferation on day four at concentrations 0.001-10 nM. Even 
the exclusion of one outlier yielded a significant increase in NF1-/- Schwann cell 
proliferation up to 40-56%.  
New treatments are needed to diminish the tumor burden of NF1 patients. The 
conventional treatments include surgical or laser removal of the tumor. A naturally 
occurring metabolite, 2-methoxyestradiol (2ME2), is found at low levels in human 
plasma and at a ten times higher levels during pregnancy (Berg and Kuss, 1992). An 
analogue of 2ME2, STX3451 [(2-(3-bromo-4,5-dimethoxybenzyl)-7-methoxy-6-
sulfamoyloxy-1,2,3,4-tetrahydroisoquinoline)] was found to induce apoptosis in 
MPNST cell lines, in cells derived from benign plexiform neurofibromas, and other 
tumor-deriver NF1 cell lines, and it was shown to disrupt actin- and microtubule-based 
cytoskeletal structures and to inhibit PI3 and mTOR signaling pathways (Shen et al., 
2015). Treatment with 2ME2 reduced even hormone-responsive cancer tumor growth 
(Qadan et al., 2001). This treatment could be speculated to help to decrease 
neurofibroma growth in a topical formula. 
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5.3 The effect of testosterone on the proliferation of NF1+/- and NF1-/- 
Schwann cells 
Neurofibroma-derived Schwann cells, whose both NF1 alleles were mutated, responded 
to testosterone by increased proliferation. Our results elucidate the proliferation 
mechanism of NF1-/- Schwann cells and may pave the way for future therapeutic 
approaches. Specifically, the effect of testosterone on the proliferation of human NF1+/- 
Schwann cells after two or four days of treatment with concentrations 0.001-10 nm had 
no consistent effect. However, testosterone increased NF1-/- Schwann cell proliferation 
after two days by 15 – 22%. In addition, after four days of treatment, the proliferation of 
NF1-/- Schwann cell increased up to 110%. There was some variation on day four 
results, which showed one cell line reacting more strongly to hCG compared to the 
other cell lines. Yet, exclusion of it on this cell line yielded a significant increase in 
NF1-/- cell proliferation, which was still up to 49-60% compared to vehicle control.  
The neck, head, back, shoulders, chest, abdomen, limbs, and face are common locations 
of benign neurofibromas (Bongiorno et al., 2010; Cannon et al., 2018). It has been 
shown that the number and size of neurofibromas increased especially in the back and 
abdominal area in an 8-year follow-up study (Cannon et al., 2018). Puberty- and sex 
hormone-related diseases, such as acne, locate to the same areas of skin. Even if acne 
and neurofibromas are two totally different skin-related diseases, androgens play an 
important role in both of them. Hormones stimulate the sebaceous glands of the hair 
follicles, which are androgen target tissues, and this further increases the production of 
the sebum leading to acne (Lai et al., 2012). The circulating testosterone, DHEA, and 
androstenedione can be converted into testosterone, which is catalyzed further into DHT 
with 5α-reductase in skin sebocytes, excretory duct cells of sweat glands, dermal papilla 
cells, endothelial cells of small vessels, and Schwann cells of cutaneous myelinated 
nerves (Asada et al., 2001; Eicheler et al., 1995; Luu-The et al., 1994; Zouboulis et al., 
2007). The mechanism between AR and acne is still unclear, and it has been suggested 
that AR enhances growth factors of certain cells. The origin of neurofibromas from hair 
follicles (Jouhilahti et al., 2011a) and skin poses the question that the growth of 
neurofibromas could be inhibited by preventing the action of androgens in hair follicles, 
because it has been shown that inhibiting AR from follicles at least decreases sebocyte 
activity (Lai et al., 2012). Estrogen-containing oral contraceptives decrease the levels of 
free testosterone by increasing the hormone binding globulin that has a positive effect in 
the treatment of acne disease in women (Trivedi et al., 2017). A study related to 
contraceptives and NF1 disease has indicated that estrogen-containing oral 
contraceptive has no influence on the size of neurofibromas (Lammert et al., 2005b). It 
can be speculated that this is also due to the ability of estrogen-containing 
contraceptives to increase the hormone-binding globulin, and that decrease the amount 
of free testosterone further.  
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NF1-related neurofibromas increase in size and amount during puberty, and this might 
be explained by the fact that before puberty, the testosterone levels are low and at the 
beginning of puberty, GnRH stimulates LH and FSH in the pituitary to produce 
testosterone in testis, and the level of testosterone continues to grow until the age of 40 
(Kelsey et al., 2014). In addition, aromatase enzyme can convert testosterone into 
estradiol in different tissues and cells, such as neuronal cell bodies and presynaptic 
terminals, astrocytes, and adipose tissue (Balthazart and Ball, 2006; Garcia-Segura et 
al., 1999; Lee et al., 2013).  
5.4 The effect of human chorionic gonadotropin (hCG) on the 
proliferation of NF1+/- and NF1-/- Schwann cells 
The size and amount of neurofibromas has been reported to increase during pregnancy 
(Dugoff and Sujansky, 1996; Xiong et al., 2015). The level of different sex hormones 
changes during pregnancy, but the pregnancy hormone called hCG has not been studied 
in this context. hCG is secreted from the placenta syncytiotrophoblast cell layer and is 
responsible for embryo implantation through maintenance of the corpus luteum and its 
progesterone stimulation, fetal growth, angiogenesis and continuation of the pregnancy 
(Cole, 2010; Strott et al., 1969). The level of hCG reaches its peak during the first 
trimester.  
Our results revealed that two- and four-day treatment of NF1+/- Schwann cells with hCG 
did not have an effect on the proliferation of the cells. Interestingly, hCG increased the 
proliferation of NF1-/-Schwann cells already after two days by 29 - 51%. On day four, 
the highest concentration of hCG, 100 nm, had no such effect on the cell proliferation. 
However, hCG concentrations of 0.001-10 nM increased significantly the proliferation 
of NF1-/- Schwann cells up to 170%.  
This is the first study to address the influence of hCG on Schwann cells, and more 
specifically on NF1+/- and NF1-/- Schwann cells cultured from neurofibromas of NF1 
patients. The influence of hCG should be studied also in normal Schwann cells. There 
are many studies on hCG concentrations during normal pregnancy. It would be 
interesting to study the hCG concentrations during a NF1 patient’s pregnancy and 
determine whether there is any difference compared to normal pregnancy.  
5.5 Complexity of Schwann cell development in NF1 neurofibroma 
formation 
A complete loss of neurofibromin leads to uncontrollable Ras signaling and further to 
vulnerable responses to different growth factors, such as sex hormones. This effect was 
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seen in increased proliferation of NF1-/- Schwann cells, but also in unresponsiveness of 
NF1+/- Schwann cells towards the tested sex hormones. Estradiol, testosterone, and hCG 
are known to interact with the Ras pathway (Driggers and Segars, 2002; Fan et al., 
2008; Liao et al., 2013), but also through several different signaling pathways, such as 
Ras/Raf/MEKK/ERK, p38 MAPK, PI3K/Akt, PKC, and cAMP (Basualto-Alarcón et 
al., 2013; Choi and Smitz, 2014; Liu et al., 2006; Marino et al., 2006; Pike et al., 2008; 
Walker, 2011). Neurofibromin plays a role in these pathways (Helfferich et al., 2016), 
which raises the possibility whether we could decrease NF1+/- and NF1-/- Schwann cell 
proliferation with different inhibitors as a purpose to find therapeutic targets to decrease 
the amount and size of neurofibromas. The Ras pathway and downstream signals of Ras 
have been studied in a variety of human tumors. Especially, the Ras/Raf/MEK/ERK 
pathway is involved in cell proliferation and further in the development of tumors into 
MPNSTs (Farid et al., 2014; McCubrey et al., 2007). Investigating the Ras-deficient 
pathways may produce critical information, but also lead to knowledge how to inhibit of 
hyperactive cells and different lesions of the NF1 disease. Promising results have been 
already gained with a MEK inhibitor, which inhibited the growth of the tumors, reduced 
the number of blood vessels, and the volume of tumors (Dombi et al., 2016; Jessen et 
al., 2013). 
It is also important to understand the overlapping pathophysiology of sex hormones and 
other NF1-related tumors based on similarity of the cell composition, e.g., Schwann 
cells of the tumors. It has been shown that MPNST responded to the estrogen antagonist 
tamoxifen treatment in an ER-independent manner (Byer et al., 2011). This raises the 
possibility that a hormone antagonist treatment could decrease the size of 
neurofibromas. After all, NF1 is a hormone-related disease.  
The amount of neurofibromas and the severity of the disease vary even among the 
members of the same family. Together with other major life transitions of puberty, 
manifestation of the neurofibromas make early puberty a difficult time. Stress exposure 
in puberty may cause responses to gonadal hormones and modify ER density especially 
in brain areas (Holder and Blaustein, 2014). Emotional and physiological responses go 
hand-in-hand. This should be considered as a very significant aspect in this disease, and 
luckily there are studies that highlight the importance QoL in patients with NF1 
(Wolkenstein et al., 2001).  
5.6 Curved and branched actin architecture in human osteoclasts 
The function of osteoclasts culminates in the dynamic structure of actin. The familiar 
osteoclast actin structure podosome belt consists of F-actin cores called podosomes and 
loose F-actin cloud instantly on top of the podosomes (Saltel et al., 2008). The actin 
structure is different on glass or on bone. This is because osteoclast forms a bone-
31123633_Vaitoskirja_Paula_Pennanen_Laaketiet_tdk_sisus_B5_1705.indd   51 17.5.2019   8.20
52 Results and Discussion  
anchored adhesion structure called the SZ between bone and osteoclast to enable bone 
resorption (Lakkakorpi and Väänänen, 1991; Takito et al., 2018). However, osteoclasts 
have also been studied also on glass, which enables a deeper insight to the inside of the 
cell. In the present study, we used confocal and STED microscopy to investigate the 
osteoclast actin structure on glass. The STED microscopy images revealed that 
osteoclast actin was curved and branched from bottom to top of the cell instantly in the 
vicinity of membrane ruffles in the cell periphery. The comprehensive curved and 
branched actin structure may allow the cell to remodel itself rapidly in response to cell 
migration and fusion. STED imaging results in super-resolution images that have 
bypassed other light microscopic imaging techniques. Because of this, we find it 
tempting to speculate that the actin cloud was first named as a cloud instead of seeing 
the whole actin structure from the bottom to the top of the cell. 
5.7 Macrophages and keratinocytes branched actin structure 
The findings in osteoclasts of curved and branched actin structures raised the question 
whether this kind of actin structure is specific to osteoclasts. To study other cell types, 
we differentiated macrophages from human peripheral blood and cultured keratinocytes 
from human skin samples. Both of these cell types showed curved and branched actin 
structure. The cytoskeleton plays several roles in the cells by organizing cell contents, 
connecting the cell to external environment and allows cell movement and changes in 
cell shape (Fletcher and Mullins, 2010). The cell cytoskeleton is studied usually in vitro, 
because it is very difficult to study in living organisms and tissues. Confocal and STED 
microscopy enable a more precise study of the cell. Thus, they are important techniques 
to expand our knowledge about the cytoskeleton and understanding cellular behavior. 
5.8 The expression of c-Src, cortactin, cofilin, and ARP2/3 in 
osteoclast actin structure 
The osteoclast actin cytoskeleton undergoes dynamic changes during cell migration, 
movement, fusion, and resorption (Teitelbaum, 2011). We studied the actin related 
proteins, which modify the structure of actin. c-Src rearranges and remodels actin 
filaments, cortactin acts with c-Src and promotes actin polymerization, cofilin severs 
actin filaments, and ARP2/3 branches actin (Daly, 2004; Destaing et al., 2008; Pavlov et 
al., 2007; Smith et al., 2013). Our results were in accordance with previous studies on 
the function of the actin-related proteins. Double labeling for actin and c-Src showed 
that they colocalized in the periphery of the cell, and it gathered around the nuclei. 
Actin and cortactin colocalized also in the cell periphery and around the nuclei. Cofilin 
and actin did not colocalize, but cofilin was found in the middle of the cell and nearby 
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nuclei. We suggest that the location of c-Src and cortactin enables changes in cell actin 
structure, when the cell forms its shape and contacts with other cells. ARP2/3 appeared 
abundantly in the substratum level of the osteoclast and in the branching points of the 
actin network. We suggest that ARP2/3 is needed, especially when the osteoclast 
detaches from the substratum and during cell movement. In addition, the abundant 
occurrence of c-Src, cortactin and cofilin in the vicinity of nuclei may suggest that they 
are involved in the movement of nuclei together with actin (Dupin et al., 2011; 
Gundersen and Worman, 2013). It would be interesting to study osteoclast nuclei 
positioning and movement in live cell imaging with osteoclasts, which are 
multinucleated cells and fuse with each other.  
5.9 Micrometer level actin-rich tubes between two osteoclasts 
Tunneling nanotubes (TNTs) are actin-rich structures, which transport small molecules, 
proteins, vesicles, and different cellular components from one cell to another through a 
nanometer-level intracellular tunnel (Dupont et al., 2018). Our findings revealed actin-
rich micrometer level tubes (MLTs), which bridged between two osteoclasts above the 
substratum level and were enclosed with membranes of the connected cells. 
Interestingly, nuclei were seen in the vicinity of the MLTs, and they were surrounded 
by curved and branching actin. Compared to several TNTs per cell, only one MLT was 
seen at a time. The size of the MLTs was about 1–5 µm and the length was up to 40 µm, 
which is greater than the usual size 50-200 nm size of TNTs (Gerdes et al., 2013). 
Because TNTs transport small structures of the cell, we speculated that MLTs may 
transport bigger structures, such as nuclei. 
5.10 Nucleus inside of the micrometer tubes 
The larger size of MLTs compared to TNTs raised the question about the function of 
these tubes. Expectedly, we observed nuclei inside of these MLTs in stained cell 
images. Nuclei were elongated inside the tubes and round inside the osteoclasts. The 
nuclei seen inside of the curved and branched actin nest in the vicinity of MLTs suggest 
the possibility that they transport nuclei. We speculate that these MLTs are used in cell 
fusion and communication among neighboring cells.  
5.11 Signaling pathway studies of osteoclast differentiation 
Studying of signaling pathways is complicated because of the multiple crosstalk with 
other signaling pathways. However, it helps us to understand how we could control 
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cellular behavior. Osteoclasts are responsible for bone resorption and increased bone 
resorption may lead to osteoporosis (Kling et al., 2014). Most studies related to 
osteoclast signaling pathways have been carried out using cultured rodent osteoclasts. 
Understanding the differences between rodent and human studies allows us to carry out 
more accurate studies. Mononuclear cell progenitors from human peripheral blood were 
cultured on glass and bovine bone slices in the presence of RANKL and M-CSF to 
differentiate osteoclasts in order to understand the role of Ras/Raf/MEK/ERK, PKC, 
PI3K/Akt/mTOR, and p38 signaling pathways in osteoclast differentiation (Figure 8). 
Furthermore, abnormalities in signaling caused by the NF1 mutations were elucidated 
by comparing osteoclasts of control persons and NF1 patients under the influence of 
certain signaling pathway inhibitors. The purpose of this study was to obtain detailed 
information and a framework, which we can use to study cellular function and disease 
mechanisms. Our results showed that viable osteoclasts were seen in all of the tested 
conditions, suggesting low levels of toxicity. Inhibition of the most signaling pathways 
affected the differentiation of osteoclasts. The specific results about each pathway are 
explained below. 
 
Figure 8. The studied pathways and inhibitors of osteoclastogenesis. (Modified from the 
original publication III.) 
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5.12 The effects of inhibitors of PKC, MEK, PI3K, and mTOR on 
osteoclast differentiation 
Osteoclast differentiation is mediated through many signaling pathways (Figure 7) (Kim 
and Kim, 2016). Previous studies on murine osteoclasts have shown that inhibition of 
MEK affects ERK1/2 phosphorylation (Chappell et al., 2011) and decreases 
osteoclastogenesis (Amano et al., 2015; Breitkreutz et al., 2007). The inhibition of PKC 
decreased the number of osteoclasts and phosphorylation of ERK1/2 in murine cells 
(Shin et al., 2014). Parallel results have been gained from rodent studies, where PI3K 
was inhibited, and the number of osteoclasts decreased (Moon et al., 2012; Xing et al., 
2016). In addition, studies using rodent osteoclasts showed that the inhibition of mTOR 
decreased osteoclast differentiation (Dai et al., 2017; Zhang et al., 2017). To evaluate 
the role of the same signaling pathways in human osteoclasts, we examined the effects 
of inhibition of PKC (GÖ6976), MEK (PD98059 or U0126), PI3K (LY294002), and 
mTOR (Rapamycin) on osteoclast differentiation of control persons and NF1 
osteoclasts. Therefore, we differentiated osteoclasts on glass for 4-5 days. Visual 
inspection and counting of the control cells revealed that the number of osteoclasts 
decreased, when PKC and MEK pathways were inhibited. However, inhibition of PI3K 
and mTOR did not significantly affect the number of osteoclasts. The inhibition of 
PKC, MEK, PI3K, and mTOR in Ras-deficient cells of NF1 patients decreased 
significantly the number of osteoclasts and induced a distinct decrease in 
phosphorylation of ERK1/2 with all of the used inhibitors. 
The Ras/Raf/MEK/ERK pathway is strongly related with the NF1 disease, because loss 
of the neurofibromin leads to up-regulation of the Ras pathway (Boyd et al., 2009). 
Therefore, we speculate that the inhibition of PKC, MEK, PI3K, and mTOR in NF1-
deficient cells functions as a feedback system through hyperactive Ras, and manifests as 
decreased phosphorylation of ERK1/2 occurs. 
To investigate whether inhibition of PKC, MEK, PI3K, and mTOR has an effect on the 
phosphorylation of ERK1/2, Akt, or p38 MAPK, western blot studies were carried out. 
These results showed that inhibition of MEK, PI3K, and mTOR had no effect on the 
phosphorylation of ERK1/2 or p38 MAPK despite the decreased number of healthy 
osteoclasts. However, inhibition of MEK and mTOR increased the phosphorylation of 
Akt in cells from control persons. It can be speculated that increased phosphorylation of 
Akt is due to interaction of Ras/PI3K/Akt and Ras/Raf/MEK/ERK1/2 pathways and 
also the ability of mTOR to regulate the activity of Akt (McCubrey et al., 2012). The 
combination of inhibitors of mTOR and MEK decreased the number and 
phosphorylation of Akt of control osteoclasts even more. We suggest that the inhibition 
of MEK activates the Akt/mTOR pathway during healthy osteoclast differentiation. 
This phenomenon has also been seen in a hematopoietic IL-3/GM-CSF-dependent 
murine myeloid FDC-P1 cell line (Shelton et al., 2003).  
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Inhibition of PKC decreased the number of control cells and had no effect on the 
phosphorylation of ERK1/2, Akt, or p38, which led us to speculate about an 
independent role of PKC in healthy osteoclast differentiation.  
Monitoring the morphology of the cells is essential for successful cell culture 
experiments to learn about the actual morphology of the cells, and, moreover, to 
confirm the well-being of the cells. Monitoring of the inhibitor-treated cells revealed 
viable and healthy-looking cells in all cases. Unexpectedly, actin staining revealed that 
treatment of the cells with inhibitors prevented the actin ring formation. We draw the 
conclusion that inhibitors were not toxic to the cells, but the genuine mission of 
osteoclasts, which is bone resorption, is infeasible. Previous studies related to osteoclast 
signaling and inhibition of PKC, MEK, PI3K, and mTOR have been performed using 
rodent osteoclasts. Our data shows a similar regulation in human osteoclasts. 
5.13 The effects of inhibition of p38 MAPK on osteoclast 
differentiation 
A following subproject of this thesis was to examine the effects of inhibition of p38 
MAPK with inhibitors of SB203580 and BIRB796 on control and NF1 osteoclast 
differentiation. p38 MAPK signaling plays an important role in osteoclast formation and 
maturation (Cong et al., 2017). RANKL attachment into RANK interacts with an 
adapter protein TRAF6, which phosphorylates p38 MAPK in osteoclasts precursors 
(Kim and Kim, 2016). It has been shown that inhibition of p38 MAPK blocks osteoclast 
differentiation (Choi et al., 2013; Li et al., 2002; Matsumoto et al., 2000) while its 
activation increases survival of osteoclasts (Yamashita et al., 2008). However, these 
experiments have been carried out with rodent cells or in vivo experiments with mice. 
We were interested in comparing monocytes isolated from peripheral blood of control 
persons and NF1 patients, once the cells were differentiated into osteoclasts and p38 
MAPK signaling of differentiated cells was interfered by chemical inhibitors.  
The number of osteoclasts increased significantly when control and NF1 cells were 
treated with p38 MAPK inhibitors. Visual inspection of the cells revealed that p38 
MAPK treatment produced osteoclasts, which were larger in size compared to the cells 
without treatment. When osteoclast differentiation was delayed apparently because of 
donor variability, only precursor cells were observed in the vehicle wells. However, p38 
MAPK inhibition promoted osteoclast differentiation in these cases, and led to the 
development of mature osteoclasts.  
Firm actin ring formation was revealed with actin phalloidin staining and it was still 
visible when cells were inhibited with combination of p38 MAPK and PKC, MEK or 
mTOR inhibitors. The combined inhibitor treatments kept osteoclast numbers at the 
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vehicle level. Western blot results confirmed that inhibition of p38 MAPK decreased its 
phosphorylation. In addition, a modest decrease in Akt phosphorylation was observed in 
both healthy and NF1 cells. Interestingly, p38 MAPK inhibition increased ERK1/2 
phosphorylation in control, but not in NF1 cells.  
After we showed that inhibition of p38 MAPK increased the number of osteoclasts and 
did not have an effect on actin ring formation in healthy and NF1 cells, we studied the 
function of osteoclasts on bone. The cells were cultured on bone slices for 16 days. The 
osteoclast activity was measured from cell culture media with a CTX assay, which 
showed that the inhibition of p38 MAPK blocked osteoclast activity in control and NF1 
osteoclasts. Our results showed that inhibition of p38 MAPK regulates osteoclast 
differentiation, but not the activity of the cells. 
Because there was no difference in the effects of the p38 MAPK inhibitors SB203580 
and BIRB796 and that the α isoform of p38 MAPK regulates murine osteoclasts (Böhm 
et al., 2009), it led us to speculate that human osteoclasts express p38 MAPK isoforms α 
and/or . Western blot results confirmed that inhibition of p38 MAPK decreased the 
phosphorylation of p38 MAPK. In addition, there was a decrease in the phosphorylation 
of Akt in control and NF1 cells. However, we noticed a strong interaction between 
inhibition of p38 MAPK and phosphorylation of ERK1/2, which was increased in 
control but not in NF1 patient cells. It seemed that an increased cell number correlated 
with an increased phosphorylation of ERK1/2. Based on these results, we suggest that 
inhibition of p38 MAPK and its decreased phosphorylation activated the 
phosphorylation of ERK1/2 in control cells. This result led us speculate that p38 MAPK 
interacts strongly with ERK1/2. Both p38 MAPK and ERK1/2 are responsible for 
osteoclast differentiation (He et al., 2011; Li et al., 2002). It seems that these two 
signaling pathways interact together to rescue the cell. When the other signaling 
pathway is blocked, the second one activates. Because the inhibitors were constantly in 
the culture, not even the increased phosphorylation of ERK1/2 could save the function 
of the osteoclasts. Our results revealed that p38 MAPK is an important signaling 
pathway in osteoclast differentiation. Another major finding of this study was that the 
osteoclast number correlated with the phosphorylation of ERK1/2. These observations 
lead us to speculate that ERK1/2 is a key driver of human osteoclast differentiation. 
5.14 The effects of inhibition of Ras on osteoclast differentiation 
Ras proteins belong to the small GTPases, which are the key regulators of different 
cellular events. NF1 protein neurofibromin stimulates the conversion of active Ras-GTP 
into inactive Ras-GDP (Kiuru and Busam, 2017). Many signaling pathways mediate 
through Ras, which is often upregulated in human cancer (Campbell and Der, 2004). A 
study using mouse osteoclasts showed that inhibition of Ras decreased the activation of 
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ERK, PI3K, and osteoclast survival (Bradley et al., 2008). There are very few studies 
about the inhibition of Ras and osteoclast differentiation. However, there are several 
studies of Ras downstream signals. Therefore, we studied Ras inhibition on osteoclast 
differentiation of control persons and NF1 patient cells, where the Ras pathway is up-
regulated. In this experiment, we observed that healthy cells behaved differently 
compared to Ras-deficient cells of NF1. The number and phosphorylation of ERK 
increased in control osteoclasts and decreased in NF1 cells, when cells were treated with 
a Ras inhibitor FTS. This difference may be due to the NF1-deficient and hyperactive 
Ras signaling, where the limit of the activity has already been reached because of NF1-
deficiency. Furthermore, the inhibition of Ras increased the phosphorylation of Akt in 
both cell lines. 
This study demonstrates that Ras is an important regulator of osteoclast differentiation. 
Inhibition of Ras affects downstream signals of Ras/Raf/MEK/ERK1/2 and 
Ras/PI3K/Akt but not of p38 MAPK. This let us to speculate that there is no straight 
connection from Ras to p38 MAPK signaling, but it functions through MEK/ERK1/2. 
Again we noticed a connection between the number of osteoclasts and the 
phosphorylation of ERK1/2 as an increased number of osteoclasts increased the 
phosphorylation of ERK1/2, and it was totally opposite in NF1 cells compared to 
vehicle. Inhibition of Ras decreased the number of NF1 cells and the phosphorylation of 
ERK1/2. In addition, we found that signaling in NF1 osteoclasts differed from healthy 
cells. The NF1 gene plays a role in osteoclast signaling and differentiation. Hyperactive 
Ras can lead to excess cell growth and hyperactive cells. However, our results showed 
that the role of ERK1/2 increases, when Ras is regulated with chemical inhibitors. There 
are direct and indirect ways to target Ras, where cross-talk and feedback loops 
challenge the shutting down of the Ras signaling (Simanshu et al., 2017). One way to 
influence Ras-related diseases is to pass the Ras and influence Ras downstream signals. 
There are promising results from a phase-1 study using an inhibitor of MAPK kinase 
(MEK1/2) called selumetinib in children with NF1, where symptoms caused by 
hyperactive Ras were improved because of the treatment (Dombi et al., 2016). If we do 
not find a way to affect the main cause of the disease, we can try to find a cure for the 
symptoms. This lets us to speculate that inhibition of ERK1/2 can decrease the amount 
of hyperactive osteoclasts in NF1 patients. 
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6 CONCLUSIONS 
The aim of this study was to clarify the effects of sex hormones on the proliferation of 
NF1+/- and NF1-/- Schwann cells. We also studied the role of the NF1 gene in the 
signaling and differentiation of osteoclast. In addition, the actin structure of osteoclast 
was of interest. The following conclusions were made: 
 The proliferation of NF1-/- Schwann cells increased by up to 99-170% in 
response to estradiol, testosterone or hCG treatment, while there was no 
consistent effect on the NF1+/- genotype cells. These results highlight the 
significance of sex hormones in the regulation of neurofibroma growth. This is 
also the first study to point out the effect of hCG on the proliferation of Schwann 
cells in vitro. 
 Curved and branched actin located under the membrane of the osteoclast 
extending from podosomes at the substratum level to the top of the cell. It was 
also seen inside of macrophages and keratinocytes.  
 Actin plays a role in grouping and perhaps transportation of nuclei from one 
osteoclast to another. Nuclei were observed inside of micrometer level tubes, 
MLTs, which bridged between two osteoclasts above the substratum level. 
 Of the signaling pathways explored in this study: Ras/PI3K/Akt/mTOR, 
Ras/Raf/MEK1/2/ERK1/2, calcium-PKC, and p38 MAPK affected the 
differentiation of human osteoclasts. 
 Inhibition of PKC, MEK, PI3K, and mTOR decreased the number of human 
osteoclasts. Inhibition of PKC, MEK, PI3K, and mTOR decreased the 
phosphorylation of ERK in NF1 cells. 
 The inhibition of p38 MAPK promoted differentiation but not the activity of 
human osteoclasts in samples derived from control persons and NF1 patients. 
Inhibition of p38 MAPK increased the phosphorylation of ERK in control 
osteoclasts. 
 Inhibition of Ras increased the number of healthy osteoclasts and the 
phosphorylation of ERK, whereas inhibition of Ras decreased the number of 
NF1 osteoclasts and decreased the phosphorylation of ERK. 
 The role of p38 MAPK and ERK1/2 phosphorylation as key drivers of osteoclast 
differentiation was assessed. In addition, the number of osteoclasts appeared to 
correlate with the phosphorylation of ERK1/2.  
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